

**1. Personal Data**

Leonidas Stamatatos, Ph.D.  
Fred Hutchinson Cancer Center  
Vaccine and Infectious Disease Division  
Immunology & Vaccine Development Program  
1100 Fairview Ave. N, Seattle, WA 98109-1024  
Telephone: (206) 667-2995  
Email: [lstamata@fredhutch.org](mailto:lstamata@fredhutch.org)  
Website: <https://research.fhcr.org/stamatatos/en.html>  
Place of birth: Athens, Greece

**2. Education**

1978-1982 B.Sc. Biochemistry, University of Orleans, Orleans, France  
1982-1983 M.Sc. Synthetic Organic Chemistry, University of Paris XI, Paris, France  
1984-1988 Ph.D. Biochemistry, McGill University, Montreal, Canada  
**Ph.D. Thesis:** 'Development of Cationic Liposomes to Transfer Proteins between Membranes'

**3. Postgraduate Training**

1990-1992 UCSF, Cancer Research Institute, School of Medicine  
Mentors: Nejat Düzgünes and Demetrios Papahadjopoulos  
Topics: a) Role of Membrane Lipids during Virus-Cell Fusion  
b) Mechanisms of Liposome-Opsonization and Clearance from the Blood Circulation  
1992-1994 UCSF, Cancer Research Institute, School of Medicine  
Mentors: Cecilia Cheng-Mayer and Jay A. Levy  
Topic: Structure/Function Analysis of the HIV-1 Envelope Glycoproteins

**4. Faculty Positions Held**

1996-2001 Assistant Professor, Rockefeller University, New York, NY  
2001-2006 Associate Professor, Seattle Biomedical Research Institute (SBRI), Seattle, WA  
2001-2008 Associate Professor, Department of Pathobiology, University of Washington, Seattle, WA  
2002-Present University of Washington Graduate Faculty  
2003-Present Member, Molecular & Cellular Biology Program, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA  
2006-2013 Viral Vaccines Program Director, Seattle Biomedical Research Institute, Seattle, WA  
2006-2014 Professor, Seattle Biomedical Research Institute  
2007-2019 Member, Fred Hutchinson/University of Washington Cancer Consortium  
2007-2008 Affiliate Associate Professor, Department of Global Health, University of Washington  
2008-Present Affiliate Professor, Department of Global Health, University of Washington  
2013-2014 Scientific Director, Seattle Biomedical Research Institute  
2014-2019 Professor, Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division  
2014-Present Associate Head, Immunology and Vaccine Development Program, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center

**Other positions held**

1985-1988 Teaching Assistant in Biochemistry, McGill University, Montreal, Canada

1994-1996 Research Scientist, The Aaron Diamond AIDS Research Center, New York, NY

**5. Hospital Positions Held**  
(N/A)

**6. Honors**  
1984-1986 Graduate Scholarship Award, Public Benefit Foundation “Alexandros Onassis”

**7. Board Certification**  
(N/A)

**8. Licensure**  
(N/A)

**9. Professional Organizations**

2011-2016 Faculty 1000 Medicine, Immunology Faculty, 'HIV infection & AIDS: vaccines' section

Presently American Society for Microbiology; The American Association of Immunologists; American Association for the Advancement of Science; International Society of Vaccines

**10. University Teaching Responsibilities**

Course Organizer

2003 University of Washington, Department of Pathobiology, Pathobiology 590C: “Vaccines and immunization approaches”. Credits: 1. Organizer.

2004-2006 University of Washington, Department of Pathobiology, Pathobiology 550: “Diseases of public health importance and strategies for their control”. Credits: 3. Co-organizer.

Lectures

2006-2019 University of Washington, Department of Pathobiology, Pathobiology 551: “Biochemistry and Genetics of Pathogens and Their Hosts”. Lecture on Carbohydrates (Structure and Function).

2007 and 2008 University of Washington, Department of Pathobiology, Fall Quarters. Pathobiology 550: “Diseases of public health importance and strategies for their control”. Lectures on ‘Controlling infections with vaccines: science, practice, and clinical trials’ and ‘H5N1 Influenza on the horizon’.

2008 and 2016 University of Washington, Department of Pathobiology. Pathobiology 582: “Critical thinking”.

2011 University of Washington, Department of Microbiology, Spring Quarter. MICROM 496/499, Molecular Biology and Immunology of HIV and AIDS. Topic of lecture: “Humoral Immunology / Vaccine designs to elicit antibodies”.

2023 University of Washington, Department of Global Health. Guest lecture in Pathobiology 581: “Scientific controversies in host-pathogen interactions and diseases of public health importance”.

**A. Postdoctoral Fellows and Staff Scientists**

2001-2004 Ruth McCaffrey, Ph. D. Postdoctoral fellow, Seattle Biomedical Research Institute, UW, Department of Pathobiology

2003-2004	Chuanbin Dai, Postdoctoral fellow, Seattle Biomedical Research Institute, UW, Department of Pathobiology
2003-2005	Brian Burke, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2004-2005	Rong Xu, Ph.D. Research Associate, Seattle Biomedical Research Institute, UW, Department of Pathobiology
2005-2007	Sean Gray, Ph.D. Associate Scientist, Seattle Biomedical Research Institute
2006-2009	Aaron Wallace, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2006-2010	George Sellhorn, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2007-2010	Noah Sather, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2008-2010	Pallavi Twade, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2010- 2011	George Sellhorn, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2010-2012	Sara Campbell, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2010-2011	Noah Sather, Ph.D. Staff Scientist, Seattle Biomedical Research Institute
2011-2014	Noah Sather, Ph.D. Principal Scientist, Seattle Biomedical Research Institute
2011-2012	Jennifer Hoot, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2011-2014	Andrew McGuire, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2012	Florie Greinhofer, Intern, University of Applied Sciences Weihenstephan in Freising, Germany
2012-2014	Anita Dreyer, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2012-2014	Miles Lange, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute
2012-2014	Brian Oliver, Ph. D. Senior Scientist, Seattle Biomedical Research Institute
2012-2020	Matthew Gray, Ph.D. Senior Staff Scientist, VIDDD, Fred Hutchinson Cancer Center
2013-2014	George Sellhorn, Ph.D. Staff Scientist, Seattle Biomedical Research Institute
2013-2014	Kristen Cohen, Ph.D. Postdoctoral Fellow, Seattle Biomedical Research Institute
2013-2014	Vladimir Vigdorovich, Ph.D. Staff Scientist, Seattle Biomedical Research Institute
2013-2014	Alka Saxena, Ph.D. Staff Scientist, Seattle Biomedical Research Institute
2013-2017	Christina Yacoob, Ph.D. Postdoctoral fellow, Seattle Biomedical Research Institute and Fred Hutchinson Cancer Center
2014-2015	Alka Saxena, Ph.D. Associate Staff Scientist, VIDDD, Fred Hutchinson Cancer Center

2014-2016	Michelle Coleman, Ph.D. Postdoctoral fellow, Fred Hutchinson Cancer Center
2014- 2016	Brandon Gallaher, Ph.D. Postdoctoral fellow, Fred Hutchinson Cancer Center
2014-2017	Andrew McGuire, Ph.D. Associate, VIDF, Fred Hutchinson Cancer Center
2015- 2018	Tara Bancroft, Ph.D. Postdoctoral fellow, Fred Hutchinson Cancer Center
2015-present	Marie Pancera, Ph.D. Principal Staff Scientist, VIDF, Fred Hutchinson Cancer Center
2017-2019	Maria Lisa Knudsen, Ph.D. Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2017-2020	Yu-Ru Lin, Ph.D. Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2018-2021	Parul Agrawal, Ph.D. Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2019-2022	Komal Dolasia, Ph.D. Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2020-2021	Madeleine Jennewein, Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2021-2022	Kristina Geiger, Ph.D. Postdoctoral fellow, VIDF, Fred Hutchinson Cancer Center
2021-present	Parul Agrawal, Ph.D. Staff Scientist, VIDF, Fred Hutchinson Cancer Center
2022-present	Latha Siddaramaiah, PhD. Staff Scientist, VIDF, Fred Hutchinson Cancer Center

**B. Graduate Students**

2002-2007	Nina R. Derby, Graduate student, Seattle Biomedical Research Institute, University of Washington, Department of Pathobiology
2006-2010	Lance Kao Ching, Graduate student, Seattle Biomedical Research Institute, University of Washington, Department of Global Health
2007-2008	Jakob Peter Armann, MD/Ph.D. Student, Munich University Germany
2008-2012	Iliyana Mikell, Graduate student, Seattle Biomedical Research Institute, University of Washington, Department of Global Health
2009-2010	Thaddeus Davenport, Graduate student, Seattle Biomedical Research Institute, University of Washington, Department of Global Health
2009-2013	Kristen Cohen, Graduate student, Seattle Biomedical Research Institute RI, University of Washington, Department of Global Health
2016-2020	Rachael Parks, Graduate student, University of Washington, Department of Global Health

Graduate Student Rotations

2002 (Winter quarter)	Nina Derby, University of Washington, Department of Pathobiology
2002 (Spring quarter)	Wendy Blay, University of Washington, Department of Pathobiology
2003 (Fall quarter)	Sam Pine, University of Washington, Department of Pathobiology

2004 (Fall quarter)	Amber Randal, University of Washington, Department of Pathobiology
2005 (Summer quarter)	Sheri Wardwell, University of Washington, Department of Pathobiology
2006 (Winter quarter)	Lance Kao Ching, University of Washington, Department of Global Health
2006 (Fall quarter)	Katie Bosch, University of Washington, Department of Pathobiology
2008 (Winter quarter)	Iliyana Mikell, University of Washington, Department of Global Health
2008 (Fall quarter)	Tad Davenport, University of Washington, Department of Global Health
2009 (Fall quarter)	Kristen Cohen, University of Washington, Department of Global Health
2016 (Winter quarter)	Jiho Kim, University of Washington, Department of Global Health
2016 (Autumn quarter)	Daniel Ellis, University of Washington and Fred Hutchinson Cancer Research Center, Molecular and Cellular Biology Program
2019 (Fall quarter)	Mark Langowski, University of Washington and Fred Hutchinson Cancer Research Center, Molecular and Cellular Biology Program

### **C. Graduate student committee membership**

2000	Member, Doctoral thesis committee, Laboratory of Cellular Physiology and Immunology, The Rockefeller University: Lei Zhong
2002-2006	Member, Doctoral thesis committee, Department of Pathobiology, University of Washington: Pushpa Jayaraman
2002-2007	Member, Chair, Doctoral thesis committee, Department of Pathobiology, University of Washington: Nina Derby
2004-2007	Member, Doctoral thesis committee, Department of Immunology, University of Washington: Blythe Sather
2004-2008	Member, Co-Chair, Doctoral thesis committee, Department of Pathobiology, University of Washington: Tsai-Yu Lin
2006-2010	Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Lance Ching
2006-2012	Member, Doctoral thesis committee, Department of Pathobiology, University of Washington: Joel Janes
2007-2010	Member, Master thesis committee, Department of Pathobiology, University of Washington: Katie Bosch
2008- 2009	Member, Master thesis committee, Department of Pathobiology, University of Washington: Travis Beckett
2008-2012	Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Iliyana Skorcheva
2008-2012	Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Iliyana Mikell
2009-2010	Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Thaddeus Davenport
2009- 2011	Member, Doctoral thesis committee, Department of Biochemistry,

2009-2013	University of Washington: Mihai L. Azoitei Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Kristen Cohen
2010-2014	Member, Doctoral thesis committee, Department of Pathobiology, University of Washington: Maxwell Omenda
2010-2015	Member, Doctoral thesis committee, Department of Pathobiology, University of Washington: Leslie Goo
2011-2015	Member, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Lianna Wood
2012-2013	Member, Doctoral thesis committee, Department of Biochemistry, University of Washington: Christopher Thomas Carrico
2015-2018	Member, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Emily Cage
2016-2020	Member, Chair, Doctoral thesis committee, Department of Global Health, Pathobiology Program, University of Washington: Rachael K. Parks
2017	Karolinska Institute, Stockholm, Sweden. PhD Thesis Opponent for Paola Andrea Martinez Murillo: "B cell fate following immunization: from memory B cells to plasma cells".
2017-2019	Member, Doctoral thesis committee, Department of Statistics, University of Washington: Amrit Dhar
2019-2021	Member, Scientific Advisory Committee, Jim B. Boonyaratanakornkit, Clinical Research Fellow, FHCRC
2019- 2023	Member, Doctoral thesis committee, Department of Biochemistry, University of Washington: Jung Ho Chun
2021	External Reviewer, Ph.D. Thesis, Oluwarotimi Omorodion, Ian Wilson Lab, The Scripps Research Institute.
2021-present	Member, Doctoral thesis committee, Department of Biochemistry, University of Washington: Mark Langowski
2022	External Reviewer, Ph.D. Thesis, Ge Song, Dennis Burton Lab, The Scripps Research Institute.
2022-present	Co-supervisor, Ph.D. Thesis committee member, Laura Eiben, Karolinska Institute, Sweden.
2022-present	Ph.D. Thesis committee member, Ashwin Skelly, UPenn.
2024	External Reviewer, Ph.D. Thesis, Manyuan 'Krystal' Ma, William Schief Lab, The Scripps Research Institute.

#### D. Undergraduate Students

1996, 1997	Amy Ly, Summer rotation, ADARC
2002	Raegan Robinson, Seattle Biomedical Research Institute, STAR summer program, University of Washington
2003	Luke Wanami, Summer rotation, Seattle Biomedical Research Institute
2004	Miranda Bethay, Seattle Biomedical Research Institute, STAR summer program, University of Washington
2005	Brianne Chittenden, SBRI, STAR summer program, University of Washington

2005	Brianne Chittenden, Seattle Biomedical Research Institute, University of Washington, Undergraduate Research, PABIO 499, Autumn, Fall, and Winter quarters
2005-2006	Eirini Moisy, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2005, 2006	Rachel Niec, Summer Internship, Seattle Biomedical Research Institute
2006	Giorgios Vlahogiannis, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2006	Sara Gore, Summer Internship, SBRI
2007-2008	Rozina Caridha, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2007	Blake Hovde, Summer Intern, SBRI
2008	Angeliki Mavrantoni, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2008	Stella-Christiana Chotou, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2008	Nicole Duggan, Summer Intern, Seattle Biomedical Research Institute
2009	Jenny Kehayia, Bachelor Thesis Advisor, University of Thrace, Department of Molecular Biology and Genetics, Greece
2009	Jacqueline Benthuyesen, Global Health Intern Seattle Biomedical Research Institute
2010	Kristen Frey, Global Health Intern Seattle Biomedical Research Institute
2010	Danielle LaVigne, Undergraduate Intern (ASM Microbiology Undergraduate Research Fellow)
2010	LaMarcus Ford, Seattle Biomedical Research Institute Teen Intern (through BioQuest)
2010-2011	Wesley Plinke, Undergraduate Intern
2011	Joe Lalli, Global Health Intern
2014, 2015	Jack Petersen, Summer Intern
2016	Josephine Trichka, Summer Intern
2019	Natalie C. Turner, Summer Intern
2020	Conor Kelly, International Trainee
2021	Kareena Sikka, Summer Intern
2022-2024	Kareena Sikka, Research Lab Aide
2023-present	Grace Gad, Research Lab Aide

#### 11. Editorial and Ad Hoc Responsibilities

2005-present	Editorial Board, Journal of Virology
2015-2019	Associate Editor, Frontiers in Public Health, HIV and AIDS section
2015-present	Editorial Board of Oncotarget (Immunology and Microbiology section).
2017-2019	Associate Editor, Frontiers in Immunology, Viral Immunology Section
2021	Editor, Frontiers in Immunology, Chapter on “ <i>High-throughput molecular studies of the adaptive immune functional response</i> ”
2021-present	Editorial Board, Human Antibodies
2022-present	Editorial Board, Microbiology Spectrum

Reviewer for: AIDS, AIDS Research and Human Retroviruses, J. Immunol. Methods and Expert Opinion on Biological Therapy, PLoS Path, Vaccine, Retrovirology, The Journal of Experimental Medicine, Nature Medicine, Nature Immunology, PNAS, Science, Nature, Cell, Immunity, Science, Cell Host & Microbe and many other.

## 12. Special National and International Responsibilities

### Scientific Advisory Committees

1998-2001	Member, Grant Review Committee, Elizabeth Glaser Pediatric AIDS Foundation
1999-Present	Member, Scientific Advisory Committee, American Foundation for AIDS Research
2005-2008	Member, AIDS Immunology & Pathogenesis Study Section, DAIDS
2006	Member, Scientific committee for the 24th Annual Symposium on Nonhuman Primate Models for AIDS, Atlanta, Georgia
2006	Member, External Review Panel, Nanobiology Program and Structural Biophysics Laboratory, NCI
2006	Member, NIH Site Visit of Chiron Co.'s NIH HIV Vaccine Design and Development Team project, Palo Alto, CA
2008	Participant in the NIAID, Summit on HIV vaccine research and development, Bethesda, MD
2009	Member 'Immunogens and Antigen Processing' Working Group, Global HIV Vaccine Enterprise, New York, NY, July 15-16
2013-2018	Member, Scientific Advisory Group, Dr. Pamela Bjorkman's HIV Vaccine Research and Design grant (HIVRAD)
2014	Participant in the NIAID workshop on 'Strategies to guide the antibody affinity maturation process for HIV vaccine design'
2015-2018	Member of the AIDS Vaccine Research Subcommittee (AVRS), NIH, NIAID
2015-2018	Member, Scientific Advisory Group, Dr. Richard Wyatt's (The Scripps Research Institute NIAID/HIV Research and Development (HIVRAD) grant
2022-present	Member, Scientific Advisory Group, Dr. Richard Wyatt's (The Scripps Research Institute) NIAID/HIV Research and Design (HIVRAD) grant
2023-present	Member and Chair, Scientific Advisory Group, Drs. Eric Hunter and Rama Amara's (Emory Vaccine Center) NIAID/HIV Research and Design (HIVRAD) grant
2024-present	Member, Scientific Advisory Group, Dr. Pamela Bjorkman's HIV Vaccine Research and Design (HIVRAD) grant

### Meeting Organizations/ Chair Sessions/ Pannel Participations

2010	Co-organizer of the Meeting on "Optimizing HIV Envelope Immunogens", NIH, NIAD, Rockville, MD May 3, 2010
2012	Convener of Session on the 'Ontogeny of a protective immune response to HIV'. Conference on Retroviruses and Opportunistic Infections (CROI), MA
2012	Co-Chair, Session on "B cell responses", AIDS Vaccine 2012. Boston, MA
2015	Co-Organizer of the Keystone 2015 meeting on HIV Vaccines



- 2024 B&MGF Annual Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, February 6-8, 2024. Co-chair of a session on 'Advancing new platforms and antigens for HIV vaccines'.
- 2024 B&MGF Annual Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, February 6-8, 2024. Panelist on session entitled: Using interventional studies in people with HIV (PWH) to inform preventive HIV vaccines'.
- 2024 Moderator, Session on 'The HIV Vaccine Journey - Don't stop believing' Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO

### Faculty Promotions

- 2017 External Reviewer, Promotion to Associate Professor with Tenure, Shokrollah Elahi, Faculty of Medicine and Dentistry at the University of Alberta.
- 2018 External Reviewer, Promotion of Dr. A. Oleinikov to the Full Professor rank, Florida Atlantic University
- 2019 5-Year Full Member Faculty Review, Michael Emerman, Fred Hutchinson Cancer Center, Human Biology Division
- 2019 5-Year Full Member Faculty Review, Roland K. Strong, Fred Hutchinson Cancer Research Center, Basic Sciences Division
- 2022 External Reviewer, Promotion of Dr. Michael Zwick to Associate Professor with Tenure, The Scripps Research Institute.
- 2022 Member/Committee Chair for the promotion of Dr. Martin Prlic to Full Professor, Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division.
- 2023 Member/Committee Chair for the promotion of Dr. Evan Newell to Full Professor, Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division.

### Abstract Reviews

- 2007 Abstract reviewer for the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007
- 2008 Abstract Reviewer for the XVII International AIDS Conference IAS Mexico City
- 2008 Abstract reviewer for the XVII International AIDS Conference IAS Mexico City
- 2009 Abstract reviewer for the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention - Cape Town
- 2012 Abstract reviewer for the XIX International AIDS Conference Washington DC
- 2016 Abstract reviewer for the 21st International AIDS Conference, Durban, South Africa
- 2018 Abstract reviewer for the 22nd International AIDS Conference, Amsterdam, the Netherlands

## **13. Special Local Responsibilities**

- 2007 Member of the Local Committee and Chair of a panel discussion on neutralizing antibodies, AIDS Vaccine 2007. Seattle, WA

- 2007 Organizer and moderator of a round table discussion of neutralizing antibodies during the AIDS Vaccine 2007 International Conference, Seattle, WA
- 2007 Member, Organizing committee for the AIDS Vaccine 2007 International Conference, Seattle, WA
- 2007 AIDS Science and Technology Working Group, Seattle, WA
- 2007-2009 Co-organizer of the CFAR/UW seminar series
- 2008 Global Health Research Congress; Seattle, WA, June 16-17, 2009. Panelist on "Vaccine Discovery and Development: Challenges and Opportunities". Title of Presentation: "The HIV neutralizing antibody perspective: Lessons learned from natural infection."
- 2011 Member, Scientific organizing committee for the 2011 NHP AIDS meeting in Seattle, WA. Co-chair, "Vaccines and Immunology session
- 2011 Member, Scientific Committee, 29<sup>th</sup> Annual Symposium on Nonhuman Primate Models for AIDS, 2011, Seattle, WA.
- 2012 CROI 2012, March 5-8, 2012, Seattle, WA. Convener of Session on the "Ontogeny of a protective immune response to HIV".
- 2012 Convener of Session on the "Ontogeny of a protective immune response to HIV", CROI 2012, Seattle, WA

### University of Washington Service

- 2002 Member, Pathobiology Faculty search committee
- 2003 Member, Pathobiology task for the "Development of departmental elective courses"
- 2005-2008 Member, Department of Pathobiology Student Affairs Committee
- 2017 Member, Admissions Committee, Molecular & Cellular Biology Program, Fred Hutchinson Cancer Research Center and UW
- 2020 Member, Admissions Committee, Molecular & Cellular Biology Program, Fred Hutchinson Cancer Research Center and UW
- 2022 Department of Global Health, Pathobiology Program, Course (PABIO 536 - Bioinformatics and Gene Sequence Analysis) evaluation
- 2023 Member, Admissions Committee, Molecular & Cellular Biology Program, Fred Hutchinson Cancer Center and UW

### Seattle Biomedical Research Institute Service (Currently, Seattle Children's Research Institute)

- 2002-2004 SBRI Seminar series co-organizer
- 2002-2008 SBRI BIACORE and Flow Cytometry Core Director
- 2004 Member, Search Committee for SBRI Recruitment
- 2004-2014 SBRI BSL3 facility Director
- 2005 Member of SBRI's Communications Advisory Group
- 2005 Member and Chair, SBRI Innovation grants 2005 review panel
- 2005-2006 Co-organizer of the 'Seattle HIV group' meetings
- 2006 Member, Protein Production Core Task Force
- 2006 Member and Chair, SBRI Viral Vaccine Program Recruiting Committee
- 2006 Member, SBRI Immunology Task Force
- 2007 Member, SBRI, Interim Operations Team
- 2008-2010 Member, SBRI Succession Planning Committee

2008-2014	Member, SBRI Leadership Team
2009	Member, Council of Scientific Advisors Organizing committee
2009	Member, SBRI, Transition Planning Committee
2013-2014	Scientific Co-Director

### **Fred Hutchinson Cancer Center Service (FHCC)**

2014-2015	Member, Search Committee for the Chief Operating Officer
2014-present	Member, Executive Committee, Vaccine and Infectious Disease Division
2014- present	Member, Steering Committee, Vaccine and Infectious Disease Division
2015-2018	Member, VIDF Faculty Retreat 2016 Planning committee
	Member, Pathogens-Cancer Working Group
2015-2022	Member, VIDF Appointments and Promotion Committee
	Chair: 2020-2021
2015-present	Member, Review panel, Vaccine and Infectious Disease Division Faculty Initiative Proposals
2016-2017	Member, Search Committee for a Senior Immunologist, VIDF,
2016-2020	Member, Antibody Technology Advisory Committee
2016-2021	Member, Shared Resources Advisory Committee
2016-2021	Member, Scientific Equipment Oversight Subcommittee
2016- 2022	Member, Executive committee, Pathogen-Associated Malignancies Initiative
2016-2023	Member, Executive Committee, Integrated Research Center in Pathogen Associated Malignancies
2018-2024	Member, Chair, Advisory Committee for Dr. Evan Newell, Associate Member
2018-present	Member, Therapeutic Products Program Steering Committee
2019	Member, Security Advisory Committee
2020	Member, COVID19-related back to work Taskforce
2020	Member, Search Committee for faculty in HIV immunology and vaccine clinical research, VIDF, Fred Hutchinson Cancer Center
2022-present	Member, Advisory Committee for Dr. Daniel Blanco-Mello, Assistant Member
2024	Member, Search Committee for Faculty in Biostatistics, VIDF, Fred Hutchinson Cancer Center

### **Ad Hoc Grant Reviews**

1998	Elizabeth Glaser Pediatric AIDS Foundation, Basic Research Grants
1999	AmFAR, Targeted Grant Cycle 26: Vaccine Development and Immune Reconstitution
1999	AmFAR, Targeted Grant Cycle 28: Biomedical Methods to Prevent the Sexual Transmission of HIV
1999	NIH, HIV Vaccine Trial Network Leadership Group
2000	AmFAR, Targeted Grant Cycle 28: Vaccine Development and Immune Reconstitution
2000	NIH, NIAID, Special Emphasis Panel, Integrated Preclinical/Clinical AIDS Vaccine Development
2002	Elizabeth Glaser Pediatric AIDS Foundation, Cycle 27 Review Grants

2002 NIH/NIAID, AIDS and Related Research Study Section ZRG1, Vaccine-development emphasis

2003 American Foundation for AIDS Research, Letters of Intent

2003 AmFAR Letters of Intent, Basic Science, Grant Cycle 35

2003 Minority Biomedical Research Support Program/ University of Puerto Rico/ Support for Continuous Research Excellence Grants, February 2003

2003 NIH/NIAID, AIDS Vaccine Grant Applications, ZRG1 Vacc 03

2003 NIH/NIAID, Special Emphasis Panel, HIV Research and Design Program

2003 NIH/NIAID, Special Emphasis Panel, Integrated Preclinical/Clinical AIDS Vaccine Development Program

2003 NIH/NIAID, ZAI1 YL-A, Primate Core Immunology-Virology Laboratories

2004 Vaccines of Infectious Diseases Study Section, NIH, NIAID

2004 AmFAR Letters of Intent, Basic Science, Grant Cycle 36

2004 NIH/NIAID, Integrated preclinical/Clinical AIDS Vaccine Development, ZAI1 EC-A, 2008 Israel Science Foundation

2009 Gates Foundation Grant Reviews

2009 NIH, Challenge Grants in Health and Science Research

2009 NIH, Special Emphasis Panel/Scientific Review Group

2010 The Wellcome Trust, Research Fellowship

2010 NIH, Special Emphasis Panel/Scientific Review, Small Business Innovation Research Contract Proposals

2010 Aids Fonds Netherlands

2011 NIAID, Special Emphasis Panel, ZRG1 AARR-E

2011 NIH, Molecular AIDS and Related Research, ZRG1 AARR-K

2012 NIAID, HIV Vaccine Research and Design (HIVRAD) Program (Po1), September 2012

2012 California HIV/AIDS Research Program; Training in basic biomedical sciences study section

2012 NIAID, Special Emphasis Panel, Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD)

2013 California HIV/AIDS Research Program; Training in basic biomedical sciences study section

2013 MRC, South Africa

2014 Aids Fonds Netherlands

2014 French National Research Agency

2014 NIH Director's Early Independence Award (DP5)

2014 WellcomeTrust

2015 NIH Director's Early Independence Award (DP5)

2015 NIH, NIAID ZAI1-JBS-A-J1 HIV Research and Design Program (Po1) (served as Acting Chair)

2015 NIH, NIAID, Special Emphasis Panel/ Scientific Review Panel

2016 NIAID, HIV Vaccine Research and Design (HIVRAD) Program (Po1)

2016 NIH/NIAID HIV/AIDS Vaccine Scholars Program (K01)

2016 NIH/NIAID Innovation for HIV Vaccine Discovery (served as Chair)

2016 Wellcome Trust

2017	Canadian Institutes of Health Research (CIHR), Innovative Biomedical and Clinical HIV/AIDS Research
2017	NIH, NIAID, HIV Vaccine Research and Design (HIVRAD) Po1 applications
2018	NIAID, Special Emphasis Panel/Scientific Review, U01 applications in response to RFA: Impact of Initial Influenza Exposure on Immunity in Infants
2019	Wisconsin National Primate Research Center, Pilot Project Grant applications review
2020	NIH, NAID, Small Business: HIV/AIDS Innovation Research Applications, ZRG1 AARR-P 11B and AARR-M(07)S
2020	NIH, NIAID, HIV Vaccine Research and Design (HIVRAD) Po1 applications
2021	University de Namur, Belgium: COVID-19 related grant application reviews
2021	NIH, “Immune Development in Early Life (IDEaL)” U01 applications
2022	The Netherlands Organisation for Scientific Research (NWO/ZonMw); Grant review for the ‘Vidi-programme’
2022	NIH, NIAID, HIV Vaccine Research and Design (HIVRAD) Po1 applications
2023	NIH, NIAID, Special emphasis panel on new animal models for HIV vaccine research
2023	NIH, NIAID, HIV Vaccine Research and Design (HIVRAD) Po1 applications
2023	Canada Biomedical Research Fund and Biosciences Research Infrastructure Fund - Stage 2: Scientific and technical Review Committee

#### 14. Research Funding

##### A. Current

2018 –2024	<b>NIH/NIAID</b>	<b>Po1 AI138212 HIV Vaccine Research and Design (HIVRAD)</b>
		“Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs”
		Role: PI
		Total Award: \$9,202,848
2019 –2025	<b>NIH/NIAID</b>	<b>Ro1 AI143370</b>
		“Neutralizing and non-neutralizing antibody effector functions in HIV infected children”
		Role: Co-Investigator
		Total Subaward: \$1,320,000
2019 –2026	<b>NIH/NIAID</b>	<b>UM1 AI144462</b>
		“Consortia for HIV/AIDS Vaccine Development”
		Role: Co-Investigator
		Total Subaward: \$785,185.16
2022 –2024	<b>FNIH/Gates</b>	<b>STAM22MRNA</b>
		“mRNA encoded HIV-1 Env-Gag virus-like-particle (VLP) vaccines”
		Role: Co-Investigator
		Total Subaward: \$517,166
2024 - 2029	<b>NIH/NIAID</b>	<b>Ro1 AI177095</b>

- “Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization”  
 Role: PI  
 Total Award: \$3,302,909
- 2023 - 2027 **NIH/NIAID U19 AI174242 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD)**  
 “Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs”  
 Role: PI  
 Total Award: \$9,840,003 (Includes a \$1,630,132 Supplemental Award)
- 2024-2029 **NIH/NIAID R01 AI83406-01**  
 “Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting”  
 Role: Co-PI  
 Total Stamatatos Funds: \$1,198,901

**B. Pending****C. Past**

- 1995-1998 **AmFAR 70479**  
 “Structure-Function Relation of HIV-1 virion-gp120”  
 Role: PI
- 1996-1998 **PAF 50617**  
 “Antibody-Mediated Enhancement of HIV-1 Infection”  
 Role: PI
- 1997-1999 **NIH R21 AI42670**  
 “A Novel Strategy to Deliver Antigens to Dendritic Cells”  
 Role: PI
- 1998-1999 **AmFAR 02572**  
 “Antibody Responses to Oligomeric HIV Envelope Forms”  
 Role: PI
- 1998-2000 **NIH R44 AI40551**  
 “Designer DNA Binding proteins targeting HIV Genes”  
 Role on Project: Lead-Investigator
- 1998-2003 **NIH P30 AI42848**  
 Columbia-Rockefeller Center for AIDS research  
 Role on Project: Co-Director
- 1999-2001 **NIH R21 AI044309**  
 “Antigenicity of HIV-1 Modified Envelopes”  
 Role: PI
- 2000-2005 **NIH R01 CA72822**  
 “Structure/Function Relationship of HIV-1”  
 Role on Project: Co-Investigator
- 2000-2013 **NIH R01 AI047708**  
 “Vaccine Efficacy of Modified HIV Envelopes”  
 Role: PI
- 2002-2004 **NIH R21 AI053810**  
 “Neutralizing MAbs elicited by modified HIV envelopes”  
 Role: PI
- 2002 –2007 **NIH R01 AI051217**  
 “Protection from SHIV-infection by CTL and antibodies”  
 Role: PI

- 2003 - 2009 **NIH** **Po1 AI054564**  
 “Combined Approach to Broadly Protective AIDS Vaccines”  
 Role: PI
- 2003 - 2016 **NIH Center for AIDS Research P30 AI27757**  
 Role on Project: Co-Investigator
- 2006 – 2012 **B&MGF** **OPP38660 L. Stamatatos (PI)**  
 “Discovery of Novel HIV Neutralizing Epitopes and their Optimal Presentation through Computational Design of Small Protein Immunogens”  
 Role: PI
- 2009 - 2014 **NIH** **Po1 AI078064/ HIVRAD**  
 "Programming HIV Immune Response for Broadly Neutralizing Antibodies by Vaccination"  
 Role on Project: Co-Investigator
- 2010 - 2015 **NIH** **R01AI081625**  
 “Monitoring the development of anti-Env Abs during HIV-infection”  
 Role: PI
- 2011 - 2018 **NIH** **Po1 AI094419 / HIVRAD**  
 “Optimizing HIV immunogen-BCR interactions for vaccine development”  
 Role: PI
- 2013-2014 **Washington Vaccine Alliance**  
 “Panning a randomly mutagenized Env library to identify novel HIV immunogens”  
 Role: PI
- 2014 -2016 **B&MGF** **OPP1114725**  
 “Generation/Isolation of Novel bNabs from Lymph Node B cells”  
 Role on Project: Co-Investigator
- 2014 - 2022 **NIH/NIAID** **U19 AI109632 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD)**  
 “Eliciting VRCO1-like bNabs by Specifically Designed Env Immunogens”  
 Role: PI
- 2016-2022 **NIH/NIAID** **2R01AI081625**  
 “Monitoring the development of anti-Env Abs during HIV-infection”  
 Role: PI
- 2017 –2023 **NIH/NIAID** **U19 AI128914**  
 “Immune Responses to Malaria and HIV Infection and Immunization”  
 Role: Co-Investigator
- 2018 - 2023 **NIH/NIAID** **R01 AI104384**  
 “Defining BCR Evolution during Immunization”  
 Role: PI

## 15. Bibliography

### A. Refereed Research Articles

1. **Stamatatos, L.**, P. Sinay, and J.R. Pogany. 1984. Synthesis of (4S,5R)-(+)-L-factor, a proposed autoregulator of anthracycline biosynthesis. *Tetrahedron* **40**:1713-1719.
2. Gagné, J., **L. Stamatatos**, T. Diacovo, S.W. Hui, P.L. Yeagle, and J.R. Silvius. 1985. Physical properties and surface interactions of bilayer membranes containing N-methylated phosphatidylethanolamine. *Biochem.* **24**:4400-4408. PMID: 4052405.
3. **Stamatatos, L.** and J.R. Silvius. 1987. Effects of cholesterol on the divalent cation-mediated interactions of vesicles containing amino and choline phospholipids. *Biochem. Biophys. Acta* **905**:81-90.

4. **Stamatatos, L.**, R. Leventis, M.J. Zukerman, and J.R. Silvius. 1988. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. *Biochemistry* **27**:3917-3925. PMID: 3415963.
5. Konopka, K., **L. Stamatatos**, C.E. Larsen, B. Davis, and N. Düzgünes. 1991. Enhancement of HIV-1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions. *J. Gen. Virol.* **72**:2685-2696. PMID: 1940866
6. Düzgünes, N., M.C. Pedroso de Lima, **L. Stamatatos**, D. Flasher, D. Alford, D.S. Friend, and S. Nir. 1992. Fusion activity and inactivation of influenza virus: kinetics of low pH-induced fusion with cultured cell. *J. Gen. Virol.* **73**:27-37. PMID: 1730942
7. **Stamatatos, L.** and N. Düzgünes. 1993. Simian immunodeficiency virus (SIVmac251) membrane lipid mixing with human CD4+ and CD4- cell lines *in vitro* does not necessarily result in internalization of the viral core proteins and productive infection. *J. Gen. Virol.* **74**:1043-1054. PMID: 8509758.
8. **Stamatatos, L.** and C. Cheng-Mayer. 1993. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity host range, and syncytium-forming ability. *Journal of Virology.* **67**:5635-5639. PMCID: PMC237967.
9. **Stamatatos, L.**, A. Werner, and C. Cheng-Mayer. 1994. Differential regulation of cellular tropism and sensitivity to sCD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. *Journal of Virology.* **68**: 4973-4979. PMCID: PMC236438
10. **Stamatatos, L.** and J.A. Levy. 1994. CD26 is not involved in infection of peripheral blood mononuclear cells by the human immunodeficiency virus type 1. *AIDS* **8**:1727-1728. PMID: 7888123.
11. Koito, A., **L. Stamatatos**, and C. Cheng-Mayer. 1995. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line tropic human immunodeficiency virus type 1 envelope glycoprotein gp120. *Virology* **206**:878-884. PMID: 7856100.
12. **Stamatatos, L.** and C. Cheng-Mayer. 1995. Structural modulations of the envelope gp120 glycoprotein of HIV-1 upon oligomerization and differential V3 loop-epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. *Journal of Virology.* **69**:6191-6198. PMCID: PMC189516.
13. Cheng-Mayer, C., R. Liu, N.R. Landau, and **L. Stamatatos**. 1997. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. *Journal of Virology.* **71**:1657-1661. PMCID: PMC191226.
14. **Stamatatos, L.**, S. Zolla-Pazner, M.K. Gorny, and C. Cheng-Mayer. 1997. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. *Virology.* **229**:360-369. PMID: 9126249.
15. Mo, H., **L. Stamatatos**, J.E. Ip, D.R. Burton, J.P. Moore, and D.D. Ho. 1997. Characterization of human immunodeficiency virus type 1 neutralization escape mutants to human monoclonal antibody IgG1b12. *Journal of Virology.* **71**:6869-6874. PMCID: PMC191968.
16. **Stamatatos, L.**, M. Wiskerchen, and C. Cheng-Mayer. 1998. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV-1 isolate on viral envelope structure, cell-entry and replication. *AIDS Res. and Hum. Retroviruses* **14**:1129-1139. PMID: 9737584.
17. **Stamatatos, L.** and C. Cheng-Mayer. 1998. An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. *Journal of Virology.* **72**:7840-7845. PMCID: PMC110102.
18. **Stamatatos, L.**, M. Lim and C. Cheng-Mayer. 2000. Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates. *AIDS Res. and Hum. Retroviruses.* **16**: 981-994. PMID: 10890360.



19. Ly, A and **L. Stamatatos**. 2000. V2 loop-glycosylation of the HIV-1SF162 envelope facilitates the interaction of this protein with the CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4-binding site antibodies. *Journal of Virology*. **74**; 6769-6776. PMID: PMC112193.
20. Ignatius, R., K. Mahnke, M. Rivera, K. Hong, F. Isdell, R. M. Steinman, M. Pope, and **L. Stamatatos**. 2000. Presentation of proteins encapsulated into sterically-stabilized liposomes by dendritic cells initiates CD8+ T cell responses in vivo. *BLOOD*. **96**; 3505-3513. PMID: 11071648.
21. Cherpelis, S., I. Shrivastava, A. Gettie, X. Jin, D. D. Ho, S. W. Barnett and **L. Stamatatos**. 2001. DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T cell-depleted rhesus macaques. *Journal of Virology*. **75**; 1547-1550. PMID: PMC114060.
- \*22. Barnett, S. W., S. Lu, I. Shrivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, A. Fong, C. Buckner, A. Ly, S. Hilt, J. Ulmer, C. Wild, J. Mascola and **L. Stamatatos**. 2001. The ability of an oligomeric HIV-1 envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following the partial deletion of the second hypervariable region. *Journal of Virology*. **75**; 5526-5540. PMID: PMC114265.
23. Cherpelis, S., X. Jin, A. Gettie, D. D. Ho, S. W. Barnett, I. Shrivastava and **L. Stamatatos**. 2001. DNA-immunization with a V2 deleted HIV envelope elicits protective antibodies in macaques. *J. Immunol. Letters*. **79**; 47-55. PMID: 11595289.
24. Shrivastava, I. K., **L. Stamatatos**, A. Fong, H. Legg, E. Kan, S. Coates, L. Leung, M. Wininger, J. Donnelly, J. B. Ulmer and S. W. Barnett. 2002. Purifications and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. *Journal of Virology*. **76**; 2835-2847. PMID: PMC135995.
25. Shrivastava, I., K. VanDorsten, L. Vojtech, S. W. Barnett and **L. Stamatatos**. 2003. Changes in the immunogenic properties of soluble gp140 HIV envelope constructs upon partial deletion of the second hypervariable region. *Journal of Virology*. **77**; 2310-2320. PMID: PMC141106.
26. Shrivastava, I. K., **L. Stamatatos**, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K. H. Roux, L. Vojtech, D. Montefiori, J. Donnelly, J. B. Ulmer and S. W. Barnett. 2003. Purification, characterization and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 Loop derived from SF162, an R5-tropic primary HIV-1 isolate. *Journal of Virology*. **77**; 11244-11259. PMID: PMC224963.
27. Gummuluru, S., M. Rogel, **L. Stamatatos**, and M. Emerman. 2003. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol dependent pathway. *Journal of Virology*. **77**; 12865-12874. PMID: PMC262553.
28. Buckner, C., L. G. Gines, C. J. Saunders, L. Vojtech, I. Shrivastava, A. Gettie, R. Bohm, J. Blanchard, S. W. Barnett, J. T. Safrin and **L. Stamatatos**. 2004. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. *Virology*. **320**; 167-180. PMID: 15003872.
29. McCaffrey, A.R., C. Saunders, M. Hensel, and **L. Stamatatos**. 2004. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. *Journal of Virology*. **78**; 3279-3295. PMID: PMC371088.
30. Gorny, M.K., **L. Stamatatos**, B. Volsky, K. Revesz, C. Williams, X. -H. Wang, S. Cohen, R. Staudinger, and S. Zolla-Pazner. 2005. Identification of a new quaternary neutralizing epitope on HIV-1 virus particles. *Journal of Virology*. **79**; 5232- 5237. PMID: PMC1069558.

31. Witvrow, M., V. Fikkert, A. Hantson, C. Pannecouque, B. R. O'Keefe, J. McMahon, **L. Stamatatos**, E. de Clercq, and A. Bolmstedt. 2005. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. *Journal of Virology*. **79**; 7777-7784. PMID: PMC1143621.
32. Saunders, C.J, R.A. McCaffrey, I. Zharkikh, Z. Kraft, S. Malembaum, B. Burke, C. Cheng-Mayer, and **L. Stamatatos**. 2005. The V1, V2, and V3 regions of the HIV-1 envelope differentially affect the viral phenotype in an isolate-dependent manner. *Journal of Virology*. **79**; 9069-9080. PMID: PMC1168758.
33. Li, M., F. Gao, J.R. Mascola, **L. Stamatatos**, V.R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K.M. Greene, M. Bilska, D. L. Kothe, J.F Salazar-Gonzalez, X. Wei, J. M. Decker, B.H. Hahn, and D.C. Montefiori. 2005. Human immunodeficiency virus type 1 *env* clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *Journal of Virology*. **79**; 10108-10125. PMID: PMC1182643.
34. Xu, R., I.K. Srivastava, L. Kuller, I. Zarkikh, Z. Kraft, Z. Fagrouch, N. L. Letvin, J. L. Heeney, S. W. Barnett, and **L. Stamatatos**. 2006. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. *Virology*. **349**; 276-289. PMID: 16527321.
35. Bolesta, E., A. Kowalczyk, A. Wierzbicki, C. Eppolito, Y. Kaneko, M. Takiguchi, **L. Stamatatos**, P.A. Shrikant, D. Kozbor. 2006. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV Env glycoprotein when combined with IL21 and IL15 gene delivery. *J. Immunol*. **177**; 177-191. PMID: PMC2504682.
36. Derby, N. R., Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and **L. Stamatatos**. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 Envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIV<sub>SF162P4</sub> and heterologous HIV-1 infection. *Journal of Virology*. **80**; 8745-8762. PMID: PMC1563892.
37. Sharma, VA., E. Kan, Y. Sun, Y. Lian, J. Cistro, V. Frasca, S. Hilt, **L. Stamatatos**, J. J. Donnelly, J. B. Ulmer, S. W. Barnett, and I. K. Srivastava. 2006. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. *Virology*. **352**; 131-144. PMID: 21894641.
38. Xu, R., I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and **L. Stamatatos**. 2006. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. *AIDS Research and Human Retroviruses*. **22**; 1022-1030. PMID: 17067273.
39. Burke, B., N. R. Derby, Z. Kraft, C. J. Saunders, C. Dai, N. Llewellyn, I. Zharkikh, L. Vojtech, T. Zhu, I K. Srivastava, S. W. Barnett, and **L. Stamatatos**. 2006. Viral evolution in macaques co-infected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies. *Virology*. **355**; 138-151. PMID: 16920175.
40. Kraft, Z<sup>@</sup>, N. R. Derby<sup>@</sup>, R. A. McCaffrey, R. Niec, W. M. Blay, N. L. Haigwood, E. Moysi, C. J. Saunders, T. Wrin, C. J. Petropoulos, M. J. McElrath, and **L. Stamatatos**. 2007. Macaques infected with a CCR5-tropic Simian/Human Immunodeficiency Virus develop broadly reactive anti-HIV neutralizing antibodies. *Journal of Virology*. **81**; 6402-6411. PMID: PMC1900107.
41. Derby, N. R., S. Gray, E. Wayner, D. Campogan, G. Vlahogiannis, Z. Kraft, S. W. Barnett, I. K. Srivastava, and **L. Stamatatos**. 2007. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. *Virology*. **366**; 433-445. PMID: PMC2048818.

42. Ching, K.L., G. Vlachogiannis, K.A. Bosch, and **L. Stamatatos**. 2008. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous HIV-1 isolates to neutralizing antibodies elicited by gp140 immunogens. *Journal of Virology*. 82; 949-956. PMID: PMC2224850.
43. Xu, Y., H. Zhu, C. K. Wilcox, A. van Wout, T. Andrus, N. Llewellyn, **L. Stamatatos**, J. I. Mullins, L. Corey, and T. Zhu. 2008. Blood monocytes harbor human immunodeficiency virus type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. *J. Inf. Diseases*. 177; 309-318. PMID: 18173363.
44. Srivastava, I.K., E. Kan, Y. Sun, V. A. Sharma, J. Cisto, B. Burke, Y. Lian, S. Hilt, Z. Biron, K. Hartog, **L. Stamatatos**, R. H. Cheng, J. B. Ulmer, and S.W. Barnett. 2008. Comparative Evaluation of Trimeric Envelope Glycoproteins Derived from Subtype C and B HIV-1 R5 Isolates. *Virology*. 372; 273-290. PMID: 18061231.
45. Kraft, Z., K. Strouss, W. Sutton, B. Cleveland, F.Y. Tso, P. Polacino, J. Overbaugh, S. L. Hu and **L. Stamatatos**. 2008. Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses. *Journal of Virology*. 82; 5912-5921. PMID: PMC2395128.
46. Polacino, P., K. Larsen, L. Galmin, J. Suschak, Z. Kraft, **L. Stamatatos**, D. Anderson, S. W. Barnett, R. Pal, K. B. A. H. Bandivdekar, C. J. Miller, and S.-L.Hu. 2008. Differential pathogenicity of SHIVSF162P4 infection in pig-tailed and rhesus macaques. *J. Med. Primatology*. 37 (suppl. 2); 13-23. PMID: PMC2728750.
- \*47. Sather, D.N., J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and **L. Stamatatos**. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during HIV-1 infection. *Journal of Virology*. 83; 757-769. PMID: PMC 2612355.
48. Wallace, A., and **L. Stamatatos**. 2009. Introduction of Exogenous Epitopes in the Variable Regions of the HIV-1 Envelope Glycoprotein: Effect on Viral-Infectivity and Neutralization Phenotype. *Journal of Virology*. 83; 7883-7893. PMID: PMC2715762.
49. Xu, H., L. Song, M. Kim, M. A. Holmes, Z. Kraft, G. Sellhorn, E. L. Reinherz, **L. Stamatatos** and R. K. Strong. 2010. Neutralization by the human anti-HIV antibody 4E10 depends upon MPER extraction from the viral membrane aided by lipid interactions. *Journal of Virology*. 84; 1076-1088. PMID: PMC2798360.
50. Sellhorn, G., Z. Caldwell, C. Mineart and **L. Stamatatos**. 2010. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. *Vaccine*. 28; 430-436. PMID: 19857451.
51. Blish, C. A., D. N. Sather, G. Sellhorn, **L. Stamatatos**, Y. Sun, I. Srivastava, S. W. Barnett, B. Cleveland, J. Overbaugh, and S-L Hu. 2010. Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes. *Journal of Virology*. 84; 2573-2584. PMID: PMC2820908.
52. Robinson, J.E#., K. Franco, D. Holton Elliott, M. J. Maher, A. Reyna, D. Montefiori, S. Zolla-Pazner, M K. Gorny, Z Kraft, **L. Stamatatos**. 2010. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIV<sub>SF162P4</sub>. *Journal of Virology*. 84; 3443-3453. PMID: PMC2838135.
53. Sather, D. N., and **L. Stamatatos**. 2010. Epitope Specificities of Broadly Neutralizing Plasmas from HIV-1 Infected Subjects. *Vaccine* 28S; B8-B12. PMID: PMC2879344.
54. Ching, L., and **L. Stamatatos**. 2010. Alterations in the Immunogenic Properties of Soluble Trimeric Human Immunodeficiency Type-1 Envelope Proteins Induced by Deletion or Heterologous Substitutions of the V1 Loop. *Journal of Virology*. 84; 9932-9946. PMID: PMC2937763.

55. Correia, B. E., Y-E A. Ban, M. A. Holmes, H. Xu, K. Ellingson, Z. Kraft, C. Carrico, E. Boni, D. N. Sather, C. Zenobia, K. Y. Burke, T. Bradley-Hewitt, J. F. Bruhn-Johannsen, O. Kalyuzhnyi, D. Baker, R. K. Strong, **L. Stamatatos**, and W. R. Schief. 2010. Computational design of epitope scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. *Structure*. 18; 1116-1126. PMID: 20826338.
56. Correia, B.E., Y.-E. A Ban, D. J. Friend, K. Ellingson, H. Xu, E. Boni, T. Bradley-Hewitt; J. F. Bruhn-Johannsen, **L. Stamatatos**, R. K. Strong, and W. Schief. 2010. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. *JMB*. 405; 284-297. PMID: 20969873.
57. Mikell, I., D. N. Sather, S. A. Kalams, M. Altfeld, G. Alter, and **L. Stamatatos**. 2011. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. *PLoS Pathogens*. 7(1); e1001251. PMCID: PMC3020924.
58. Changela, A., X. Wu, Y. Yang, B. Zhang, J. Zhu, G. A. Nardone, S. O'Dell, M. Pancera, M. K. Gorny, S. Phogat, J. E. Robinson, **L. Stamatatos**, S. Zolla-Pazner, J. R. Mascola, and P. D. Kwong. 2011. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. *Journal of Virology*. 85; 2524-35. PMCID: PMC3067962.
59. Wu,X., A. Changela, S. O'Dell, S. D. Schmidt, M. Pancera. Y. Yang, B. Zhang, M. K. Gorny, S. Phogat, J. E. Robinson, **L. Stamatatos**, S. Zolla-Pazner, P. D. Kwong, J. R. Mascola. 2011. Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. *Journal of Virology*. 85;4578-4585. PMCID: PMC3126226.
60. Malherbe, D. C., N. Doria-Rose, L. Misher, T. Beckett, W. Blay Puryear, J. O'Malley, M. Mori, I. Srivastava, S. Barnett, **L. Stamatatos**, and N. L. Haigwood. 2011. Sequential immunization with a subtype B HIV-1 Envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. *Journal of Virology*.85; 5262-5274. PMCID: PMC3094990
61. Davenport, T. M, D. Friend, K. Ellingson, H. Xu, Z. Caltwell, G. Sellhorn, Zane Kraft, R. K. Strong, **L. Stamatatos**. 2011. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific MAbs PG9 and PG16. *Journal of Virology*. 85; 7095-7107. PMCID: PMC3126577.
62. Shah A, Verma AS, Patel KH, Noel R, Rivera-Amill V, Silverstein PS, Chaudhary S, Bhat HK, **Stamatatos L**, Singh DP, Buch S, Kumar A. 2011. HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. *PLoS One*.6(6);e21261. Epub 2011 Jun 21. PMCID: PMC3119684.
63. Sellhorn, G., Z. Kraft, Z. Caldwell, K. Ellingson, C. Mineart, M. S. Seaman and D. C. Montefiori, E. Lagerquist, and **L. Stamatatos**. 2012. Engineering, expression, purification and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. *Journal of Virology*. 86; 128-142. PMCID: PMC3255899.
64. Klein, F., Christian Gaebler, Hugo Mouquet, Noah Sather, Clara Lehmann, Johannes Scheid, Zane Kraft, Yiang Liu, John Pietzsch, Arlene Hurley, Pascal Poignard, Ten Feizi, Lynn Morris, Bruce D. Walker, Gerd Fatkenheuer, Michael S. Seaman, **L. Stamatatos** and M. C. Nussenzweig. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. *J. Exp. Med.* 209; 1469-1479. PMCID: PMC3409500.
65. McClure, J., E. Lovelace, S. Elahi, N. J. Maurice, J. Wagoner, J. Dragavon, J. E. Mittler, Z. Kraft, **L. Stamatatos**, H. Horton, S. C. De Rosa, R. W. Coombs, and S. J. Polyak. 2012. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. *PLoS One*. 7(7); e41832. PMCID: PMC3404953.
66. Pissani, F., D.C. Malherbe, H. Robins, V. R. DeFilippis, B. Park, G. Sellhorn, **L. Stamatatos**, J. Overbaugh, N. L. Haigwood. 2012. Motif-optimized subtype A HIV envelope-based DNA

- vaccines rapidly elicit neutralizing antibodies when delivered sequentially. *Vaccine*. **30**: 5519-5526. PMID: PMC3447634.
67. Sather, D. N., S. Carbonetti, J. Kehayia, Z. Kraft, I. Mikell, J. Scheid, F. Klein, and **L. Stamatatos**. 2012. Broadly neutralizing antibodies developed by an HIV+ elite neutralizer exact replication fitness cost to the contemporaneous neutralization-escape virus. *Journal of Virology*. **86**: 12676-12685. PMID: PMC3497623.
  68. Mikell, I., and **L. Stamatatos**. 2012. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env glycoprotein in an HIV-1-infected subject. *PLoS One*. **7**(11): e49610. PMID: PMC3496710.
  69. Hoot, S. J<sup>@</sup>, A. McGuire<sup>@</sup>, K. W. Cohen, R. K. Strong, L. Hangartner, F. Klein, R. Diskin, J. F. Scheid, D. N. Sather, D. R. Burton, and **L. Stamatatos**. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. *PLoS Pathogens*. **9**(1): e100316. PMID: PMC3536657.
  - \*70. McGuire<sup>@</sup>, A., S. Hoot<sup>@</sup>, A. M. Dreyer, A. Lippy, A. Stuart, K. Cohen, J. Jardine, S. Menis, J. F. Scheid, A. P. West, W. R. Schief and **L. Stamatatos**. 2013. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. *The Journal of Experimental Medicine*. **210**: 655-663. PMID: PMC3620356.
  71. Jardine, J., J-P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P-S. Huang, S. MacPherson, Meaghan Jones, Travis Nieusma, John Mathison, David Baker, Andrew B. Ward, D. R. Burton, **L. Stamatatos**, D. Nemazee, I. A. Wilson, W. R. Schief. 2013. Rational HIV immunogen design to target specific germline B cell receptors. *Science* **340**: 711-716. PMID: PMC3689846.
  72. Diskin, R., F. Klein, J. A. Horwitz\*, A. Halper-Stromberg\*, N. D. Sather\*, P. M. Marcovecchio, T. Lee, A. P. West, Jr., H. Gao, M. S. Seaman, **L. Stamatatos**, M. C. Nussenzweig and P. J. Bjorkman. 2013. Restricting HIV pathways for escape using rationally-designed anti-HIV antibodies. *The Journal of Experimental Medicine*. **210**: 1235-1249. PMID: PMC3674693.
  73. Avnir, Y., Tallarico, A. T, Q. Zhu, A. S. Bennett, Wiklest, J. Sheehan, J. Sui, F. Amr, H. Chiung-yu, G. Cadwell, L. A. Bankston, A. T. McGuire, **L. Stamatatos**, G. Wagner, R. C. Liddington and W A. Marasco. 2013. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against Influenza A viruses. *PLoS Pathogens* May 2014 **10**: e1004103. PMID: PMC4006906.
  74. McGuire, T.A., Glenn, J.A, Lippy, A, and **L. Stamatatos**. 2014. Diverse recombinant HIV-1 Envs fail to activate B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. *Journal of Virology*. **88**: 2645-2657. PMID: PMC3958080.
  75. Carbonetti, S., B. Oliver, J. Glenn, **L. Stamatatos**, and N. D. Sather. 2014. Soluble HIV-1 Envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and broad, but low potency neutralizing antibodies. *PLoS One*, **9**: e86905. PMID: PMC3900663.
  76. Dugast, A-S.,\* **L. Stamatatos**\*, T. J. Suscovich, A. F. Licht, I. Mikell, M. E. Ackerman, H. Streeck, P.J. Klasse, J. P. Moore, G. Alter. 2014. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity begins during acute infection. *Eur. J. Immunol.* **44**: 2925-2937. PMID: PMC4311770.
  77. Sather, D. N., S. Carbonetti, D. Malherbe, F. Pissani, A. B. Stuart, A. J. Hessel, I. Mikell, S. A. Kalams, N L. Haigwood, and **L. Stamatatos**. 2014. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. *Journal of Virology*. **88**: 12968-12981. PMID: PMC4249098.
  78. Finton, K. A. K., D. Friend, J. Jaffe, M. Gewe, M. A. Holmes, H. B. Larman, A. Stuart, K. Larimore, P. D. Greenberg, Stephen J. Elledge, **L. Stamatatos** and R. K. Strong. 2014. Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. *PLoS Pathogens*. **10**: e1004403. PMID: PMC4177983.

79. Cohen, K.W., M. Altfeld, G. Alter and **L. Stamatatos**. 2014. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. *Journal of Virology*. **88**; 13310-13321. PMID: PMC4249103.
- \*80. McGuire, M. T<sup>@</sup>, A. M. Dreyer<sup>@</sup>, S. Carbonetti, A. Lippy, J. Glenn, J. F. Scheid, H. Mouquet, and **L. Stamatatos**. 2014. Antigen-modification regulates competition of broad and narrow neutralizing HIV antibodies. *Science*. **346**; 1380-1383. PMID: PMC4290850.
81. Chang, H. W., L. Tartaglia, J. Whitney, S.Y. Lim, S. Sanisetty, C. Lavine, M. Seaman, C. Rademeyer, C. Williamson, K. Ellingson-Strouss, **L. Stamatatos**, J. Kublin, and D. Barouch. 2015. Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. *Journal of Virology*. **89**; 1965-1974. PMID: PMC4338880.
82. Bricault, C., J. Kovacs, J. Nkolola, K. Yusim, E. Giorgi, J. Shields, J. Perry, C. Lavine, A. Cheung, K. Ellingson-Strouss, C. Rademeyer, G. Gray, C. Williamson, **L. Stamatatos**, M. Seaman, B. Korber, B. Chen, and D. Barouch. 2015. A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. *Journal of Virology*. **89**; 2507-2519. PMID: PMC4325749.
83. Cohen, K.W., A-S. Dugast, A. Galit, and **L. Stamatatos**. 2015. HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN. *J. Immunol.* **194**; 2769-2775. PMID: PMC4363079.
84. Zhou, T., R. Lynch, L. Chen, P. Acharya, X. Wu, N. A. Doria-Rose, M. Gordon Joyce, D. Lingwood, C. Soto, R. T. Bailer, M. J. Ernandes, R. Kong, N. S. Longo, M. K. Louder, K. McKee, S. O'Dell, S. D. Schmidt, L. Tran, Z. Yang, A. Druz, T. S. Luongo, S. Moquin, S. Srivatsan, Y. Yang, B. Zhang, A. Zheng, M. Pancera, T. Kirys, I. S. Georgiev, T. Gindin, H-P. Peng, A-S. Yang, NISC Comparative Sequencing Program, J. C. Mullikin, M. D. Gray, **L. Stamatatos**, D. R. Burton, W. C. Koff, M. S. Cohen, B. F. Haynes, J. P. Casazza, M. Connors, D. Corti, A. Lanzavecchia, Q. J. Sattentau, R. A. Weiss, A. P. West, Jr., P. J. Bjorkman, J. F. Scheid, M. C. Nussenzweig, L. Shapiro, J. R. Mascola and P. D. Kwong. 2015. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. *Cell*. **161**; 1280-1292. PMID: PMC4683157.
85. Dosenovic, P., L. von Boehmer, A. Escolano, J. Jardine, N. Freund, A. D. Gitlin, A. T. McGuire, D. W. Kulp, T. Oliveira, L. Scharf, J. Pietzsch, M. D. Gray, A. Cupo, M. J. van Gils, C. Liu, A. Gazumyan, M. S. Seaman, P. J. Björkman, R. W. Sanders, John P. Moore, **L. Stamatatos**, W. Schief and M. C. Nussenzweig. 2015. Immunization of HIV-1 broadly neutralizing antibodies in human Ig knock-in mice. *Cell*. **161**; 1505-1515. PMID: PMC4604566.
- \*86. McGuire, A. T<sup>@</sup>, M. D. Gray<sup>@</sup>, P. Dosenovic<sup>@</sup>, A. D. Gitlin, N. T. Freund, J. Petersen, C. Correnti, W. Johnsen, R. Kegel, A. B. Stuart, J. Glenn, M. S. Seaman, W. R. Schief, R. K. Strong, M. C. Nussenzweig, and **L. Stamatatos**. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. *Nature Communications*. **7**; 10618. PMID: PMC4770077.
87. Scharf, L., A. West, S. Sievers, C. Chen, S. Jiang, H. Gao, M. Gray, A. McGuire, J. Scheid, M. Nussenzweig, **L. Stamatatos** and P. Bjorkman. 2016. Structural basis for germline antibody recognition of HIV-1 immunogens. *eLife*. **5**; e13783. PMID: PMC4811768.
88. Hessell, A. J., D. C. Malherbe, F. Pissani, S. McBurney, S. J. Krebs, M. Gomes, S. Pandey, W. F. Sutton, B. J. Burwitz, M. Gray, H. Robins, B. S. Park, J. B. Sacha, C. C LaBranche, D. H. Fuller, D. C. Montefiori, **L. Stamatatos**, D. N. Sather and N. L. Haigwood. 2016. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. *J. Immunol.* **196**; 3064-3078. PMID: PMC4797725.
89. Vigdorovich, V., B. G. Oliver, S. Carbonetti, N. Dambrauskas, M. D. Lange, C. Yacoob, W. Leahy, J. Callahan, **L. Stamatatos**, and D. N. Sather. 2016. Repertoire comparison of the B-

- cell receptor encoding loci in humans and rhesus macaques by next generation sequencing. *Clinical and Translational Immunology*. *Clinical & Translational Immunology*. **5**: 393. PMID: PMC4973324.
90. Tian, M., C. Cheng, X. Chen, H. Duan, H-L. Cheng, M. Dao, Z. Sheng, M. Kimble, L. Wang, S. Lin, S. D. Schmidt, Z. Du, M. G. Joyce, Y. Chen, B. J. DeKosky, Y. Chen, E. Normandin, E. Cantor, R. Chen, N. A. Doria-Rose, Y. Zhang, W. Shi, W-P. Kong, M. Choe, I. S. Georgiev, P-Y. Huang, S. Jain, A. T. McGuire, E. Georgeson, S. Menis, W. R. Schief, **L. Stamatatos**, P. D. Kwong, L. Shapiro, B. F. Haynes, J. R. Mascola and F. W. Alt. 2016. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. *Cell*. **166**: 1471-1484. PMID: PMC5103708.
  91. Yacoob, C<sup>@</sup>, M. Pancera<sup>@</sup>, V. Vigdorovich, B. G. Oliver, J. A. Glenn, J. Feng, D. N. Sather, A. McGuire and **L. Stamatatos**. 2016. Differences in allelic frequency and CDRH3 composition limit the engagement of HIV Env immunogens by putative VRC01 neutralizing antibody precursors. *Cell Reports*. **17**: 1560-1570. PMID: PMC5207042
  92. Zhou, T., N. A. Doria-Rose, C. Cheng, G. B.E. Stewart-Jones, G.Y. Chuang, M. Chambers, A. Druz, H. Geng, K. McKee, Y. D. Kwon, S. O'Dell, M. Sastry, S. D. Schmidt, K. Xu, L. Chen, R. E. Chen, M. K. Louder, M. Pancera, T. G. Wanninger, B. Zhang, A. Zheng, S. K. Farney, K. E. Foulds, I. S. Georgiev, M. Gordon Joyce, T. Lemmin, S. Narpala, R. Rawi, C. Soto, J-P. Todd, C-H. Shen, Y Tsybovsky, Y Yang, P. Zhao, B. F. Haynes, **L. Stamatatos**, M. Tiemeyer, L. Wells, D. Scorpio, L. Shapiro, A. B. McDermott , J. R. Mascola and P. D. Kwong. 2017. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. *Cell Reports*.**19**: 719-732. PMID: PMC5538809.
  93. Medina-Ramirez, M<sup>\*</sup>, F. Garces<sup>\*</sup>, A. Escolano, P. Skog, S. de Taeye, I. Del Moral-Sanchez, A. McGuire, A. Yasmeen, A. J. Behrens, G. Ozorowski, T. van den Kerkhof, N.T. Freund, P. Dosenovic, Y. Hua, A. D. Gitlin, A. Cupo, P. van der Woude, M. Golabek, K. Sliepen, T. Blane, N. Kootstra, M. van Breemen, L. Pritchard, R. Stanfield, M. Crispin, A. Ward, **L. Stamatatos**, P. Klasse, J.P. Moore, D. Nemazee, M. Nussenzweig, I. Wilson, and R. Sanders. 2017. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple bNAb precursors *in vivo*. *The Journal of Experimental Medicine*. **214**: 2573-2590. PMID: PMC5584115.
  94. Avnir, Y., K. L. Prachanronarong, Z. Zhang, S. Hou, E. C. Peterson, J. Sui, H. Zayed, V. Kurella, A. T. McGuire, **L. Stamatatos**, B. J. Hilbert, M.-F. Bohn, T. F. Kowalik, J. D. Jensen, R. W. Finberg, J. P. Wang, M. Goodall, R. Jefferis, Q. K. Zhu, N. K. Yilmaz, C. A. Schiffer, and W. A. Marasco. 2017. Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-Idiotypic Antibody G6 and its Idiotope. *Cell Reports*. **21**: 3245-3255. PMID: PMC7185437.
  95. Dosenovic, P, E. E. Kara, A.-K. Pettersson, A. McGuire, M. Gray, H. Hartweger, E. S. Thientosapol, **L. Stamatatos** and M C. Nussenzweig. 2018. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen binding affinity. *Proc. Natl. Acad. Sci. USA*. **115**(18): 4743-4748. PMID: PMC5939114.
  96. Yacoob, C., M. D. Lange, K. Cohen, K. Lathia, J. Feng, J. Glenn, S. Carbonetti, B. Oliver, V. Vigdorovich, D. N. Sather<sup>#</sup>, and **L. Stamatatos**<sup>#</sup>. 2018. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of Rhesus macaques. *PLoS Pathogens*. **14**(6): e1007120. PMID: PMC6033445.
  97. Virnik, K., E. Nesti, C. Dail, A. Scanlan, A. Medvedev, R. Vassell, A. T McGuire, **L. Stamatatos**, I. Berkower. 2018. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. *Virology*. **36**: 5166-5172. PMID: 30037665.
  98. Borst, A. J., C. E. Weidle, M. D. Gray, B Frenz, J. Snijder, M. G. Joyce, I Georgiev, G Stewart-Jones, P. D. Kwong, A. T. McGuire, F. DiMaio, **L. Stamatatos**<sup>#</sup>, M. Pancera<sup>#</sup> and D. Velesler<sup>#</sup>. 2018. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. *eLife*. **7**: e37688. PMID: PMC6237438.

99. LaBranche, C.C., A. T. McGuire, M. Gray, S. Behrens, T. Zhou, Q. J. Sattentau, J. Peacock, A. Eaton, K. Greene, H. Gao, H. Tang, L. G. Perez, J. R. Mascola, B. F. Haynes, **L. Stamatatos**, and D. C. Montefiori. 2018. HIV-1 envelope glycan modifications that permit virus neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. *PLoS Pathogens*. 14(11): e1007431. PMID: PMC6237427
100. Bonsignori, M., E. Scott, K. Wiehe, D. Easterhoff, S. M. Alam, K-K.Hwang, M. Cooper, S-M. Xia, R. Zhang, D. C. Montefiori, R. Henderson, X Nie, G. D. Kelsoe, K. O. Saunders, M. A. Moody, X. Chen, M. G. Joyce, P. D. Kwong, M. Connors, J. R. Mascola, A. T. McGuire, **L. Stamatatos**, M. Medina-Ramírez, R. W. Sanders, T. B. Kepler, B. F. Haynes. 2018. Dual maturation pathways from the unmutated common ancestor of HIV-1 envelope broadly neutralizing antibodies overcome glycan barriers. *Immunity*. 49; 1-13. PMID: PMC6303191. doi.org/10.1101/530832
101. Hartweger, H., A. McGuire, M. Horning, J. Taylor, P. Dosenovic, D. Yost, A. Gazumyan, M. Seaman, **L. Stamatatos**, M. Jankovic and M. Nussenzweig. 2019. Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells. *The Journal of Experimental Medicine*. 216; 1301-1310. PMID: PMC6547862. doi.org/10.1084/jem.20190287
102. Escolano, A<sup>@</sup>., H. B. Gristick<sup>@</sup>, M. E. Abernathy, J. Merckenschlager, R. Gautam, T. Y. Oliveira, J. Pai, A. P. West, Jr., C. O. Barnes, A. A. Cohen, H. Wang, J. Golijanin, D. Yost, J. R. Keeffe, Z. Wang, P. Zhao, K-H. Yao, J. Bauer, L. Nogueira, H. Gao, A. V. Voll, D. C. Montefiori, M. S. Seaman, A. Gazumyan, M. Silva, A. T. McGuire, **L. Stamatatos**, D. J. Irvine, L. Wells, M. A. Martin, P. J. Bjorkman<sup>#</sup> and M. C. Nussenzweig<sup>#</sup>. 2019. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. *Nature*. 570; 468-473. PMID: PMC6657810.
103. Dosenovic, P., A-K. Pettersson, A. Wall, E. Thientosapol, J. Feng, C. Weidle, K. Bhullar, E. Kara, H. Hartweger, J. Pai, M. Gray, K. R. Parks, J. Taylor, M. Pancera, **L. Stamatatos**<sup>#</sup>, M. Nussenzweig<sup>#</sup>, and A. T. McGuire<sup>#</sup>. 2019. Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. *Journal of Experimental Medicine*. 216; 2316-2330. PMID: PMC6780999.
104. Bancroft, T., B. DeBuysscher, C. Weidle, A. Schwartz, A. Wall, M. D. Gray, J. Feng, H. R. Steach, K. Fitzpatrick, M. M. Gewe, P. D. Skog, C. Doyle-Cooper, T. Ota, R. K. Strong, D. Nemazee, M. Pancera, **L. Stamatatos**<sup>#</sup>, A. T. McGuire<sup>#</sup>, and J. Taylor<sup>#</sup>. 2019. Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. *Journal of Experimental Medicine*. 216; 2331-2347. PMID: PMC6780997.
- \*105. Parks, K.R., A. J. MacCamy, J. Trichka, M. Gray, C. Weidle, A. Borst, A. Khechaduri, B. Takushi, P. Agrawal, J. Guenaga, R. T. Wyatt, R. Coler, C. LaBranche, D. C. Montefiori, D. Veisler, M. Pancera<sup>#</sup>, A. McGuire<sup>#</sup> and **L. Stamatatos**<sup>#</sup>. 2019. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. *Cell Reports*. 29; 3060-3072. PMID: PMC6936959
- \*106. Seydoux, E., L. J. Homad, A. J. MacCamy, K. R. Parks, N. K. Hurlburt, M. F. Jennewein, N. R. Akins, A. B. Stuart, Y-H. Wan, J. Feng, R. E. Whaley, S. Singh, M. Boeckh, K. W. Cohen, M. J. McElrath, J. A. Englund, H. Y. Chu, M. Pancera<sup>#</sup>, A. T. McGuire<sup>#</sup> and **L. Stamatatos**<sup>#&</sup>. 2020. Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. *Immunity*. 53; 98-105. PMID: PMC7276322.
- \*107. Lin Y.-R.<sup>@</sup>, K. R. Parks<sup>@</sup>, C. Weidle, A. S. Naidu, A. Khechaduri, A. Riker, B. Takushi, J.-H. Chun, A. Stuart, P. Agrawal, M. Gray, M. Pancera<sup>#</sup>, P.-S. Huang<sup>#</sup> and **L. Stamatatos**<sup>#&</sup>. 2020. HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. *Immunity*. 53; 840-851. PMID: PMC7735217.
108. Hurlburt, K. N., Y-H. Wan, A. B. Stuart, J. Feng, A. T. McGuire, **L. Stamatatos**, and M. Pancera. 2020. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *Nature Communications*. 11; 5413. PMID: PMC7591918.



109. Ding, S., A. Laumaea, R. Gasser, H. Medjahed, M. Pancera, **L. Stamatatos**, A. McGuire, R. Bazin, and A. Finzi. 2020. Antibody binding to SARS-CoV-2 S glycoprotein correlates with but does not predict neutralization. *Viruses*. **12**; 1214. PMID: PMC692607.
110. Divine, R., H. V. Dang, G. Ueda, J. A. Fallas, I. Vulovic, W. Sheffler, S. Saini, Y. T. Zhao, I. Xavier Raj, P. A. Morawski, M. F. Jennewein, L. J. Homad, Y-H. Wan, M. R. Tooley, F. Seeger, A. Etemadi, M. L. Fahning, J. Lazarovits, A. Roederer, A. C. Walls, L. Stewart, M. Mazloomi, N. P. King, D. J. Campbell, A. T. McGuire, **L. Stamatatos**, Hannele Ruohola-Baker<sup>1</sup>, Julie Mathieu, David Veesler, David Baker. 2020. Designed proteins assemble antibodies into modular nanocages. *Science*. **372**; eabd994.
111. Seydoux, E., Y.-H. Wan, J. Feng, A. Wall, S. Aljedani, L. J. Homad, A. J. MacCamy, C. Weidle, M. D. Gray, L. Brumage, J. J. Taylor, M. Pancera, **L. Stamatatos**<sup>#</sup> and A. T. McGuire<sup>#</sup>. 2021. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. *Cell Reports*. **35**; 109084. PMID: PMC8407517. doi. 10.1016/j.celrep.2021.109084.
112. Tauzin, A., M. Nayrac, M. Benlarbi, S. Y. Gong, R. Gasser, G. Beaudoin-Bussi eres<sup>1</sup>, N. Brassard, A. Laumaea, D. V ezina, J. Pr evost, S. P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, J. Niessl, O. Tastet, L. Gokool, C. Morrisseau, P. Arlotto, **L. Stamatatos**, A. T. McGuire, C. Larochelle, P. Uchil, M. Lu, W. Mothes, G. De Serres, S. Moreira, M. Roger<sup>1</sup>, J. Richard, V. Martel-Laferr ere, R. Duerr, C. Tremblay, D. E. Kaufmann, and A. Finzi. 2021. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses. *Cell Host & Microbe*. **29**; 1-14. PMID: PMC8175625. doi: 10.1016/j.chom.2021.06.001.
- \*113. **Stamatatos, L.**,<sup>#</sup> J. Czartoski, Y-H. Wan, L. J. Homad, V. Rubin, H. Glantz, M. Neradilek, E. Seydoux, M. F. Jennewein, A. J. MacCamy, J. Feng, G. Mize, S. C. De Rosa, A. Finzi, M. P. Lemos, K. W. Cohen, Z. Moodie, M. J. McElrath<sup>#</sup>, A. T. McGuire<sup>#</sup>. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021. *Science*. **372**; 1413-1418. eabg9175.
114. Jennewein, M.F., A. J. MacCamy, N. R. Akins, J. Feng, L. J. Homad, N. K. Hurlburt, E. Seydoux, Y.-H. Wan, A. B. Stuart, V. V. Edara, K. Floyd, A. Vanderheiden, J. R. Mascola, N. Doria-Rose, L. Wang, E. S. Yang, H. Y. Chu, J. L. Torres, G. Ozorowski, A. B. Ward, R. E. Whaley, K. W. Cohen, M. Pancera, M. J. McElrath, J. A. Englund, A. Finzi, M. S. Suthar<sup>&</sup>, A. T. McGuire<sup>&</sup>, **L. Stamatatos**<sup>&#</sup>. 2021. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. *Cell Reports*. **36**; 109353 doi.org/10.1016/j.celrep.2021.109353.
115. Viant, C., T. Wirthmiller, M. A. ElTanbouly, S. T. Chen, E. Kara, M. Cipolla, V. Ramos, T. Y. Oliveira, **L. Stamatatos**, and M. C. Nussenzweig. 2021. Germinal center dependent and independent memory B cells produced throughout the immune response. *The Journal of Experimental Medicine*. **218**, (8). doi 10.1084/jem.20202489.
116. Sholkuh, A.M., A. Fiore-Gartland, E. S. Ford, M. D. Miner, Y. J. Hou, L. V. Tse, H. Kaiser, H. Zhu, J. Lu, B. Madarampalli, A. Park, F. A. Lempp, R. St. Germain, E. L. Bossard, J. J. Kee, K. Diem, A. B. Stuart, P. B. Rupert, C. Brock, M. Buerger, M. K. Doll, A. K. Randhawa, **L. Stamatatos**, R. K. Strong, C. McLaughlin, M.-L. Huang, K. R. Jerome, R. S. Baric, D. Montefiori, and L. Corey. 2021. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. *J. Clin. Microbiol* 59:e00527-21. doi.org/10.1128/JCM.00527-21.
117. Ullah, I., J. Pr evost, M. S Ladinsky, H. Stone, M. Lu, S. P. Anand, G. Beaudoin-Bussi eres, M. Benlarbi, S. Ding, R. Gasser, C. Fink, Y. Chen, A. Tauzin, G. Goyette, C. Bourassa, H. Medjahed, M. Mack, K. Chung, C. Wilen, G. A. D., J. D. Dikeakos, E. A. Bruce, D. E Kaufmann, **L. Stamatatos**, A. T McGuire, J. Richard, M. Pazgier, P. Bjorkman, W. Mothes, A. Finzi, P. Kumar and P. Uchil. 2021. Live imaging of SARS-CoV2 infection in mice reveals neutralizing antibodies require both Fab and Fc for optimal efficacy. *Immunity*. **54**; 2143-2158. doi.org/10.1016/j.immuni.2021.08.015.

118. Hastie, K.M., H. Li, D. Bedinger, S. L. Schendel, S. M. Dennison, K. Li, V. Rayaprolu, X. Yu, C. Mann, M. Zandonatti, R. D. Avalos, D. Zyla, T. Buck, S. Hui, K. Shaffer, C. Hariharan, J. Yin, E. Olmedillas, A. Enriquez, D. Parekh, M. Abraha, E. Feeney, G. Q. Horn, CoVIC-DB team, Y. Aldon, H. Ali, S. Aracic, R. R. Cobb, R. S. Federman, J. M. Fernandez, J. Glanville, R. Green, G. Grigoryan, A. G. Lujan Hernandez, D. D. Ho, K.-Ying A. Huang, J. Ingraham, W. Jiang, P. Kellam, C. Kim, M. Kim, H. Mi Kim, C. Kong, S. J. Krebs, F. Lan, G. Lang, S. Lee, C. L. Leung, J. Liu, Y. Lu, A. MacCamy, A. T. McGuire, A. L. Palser, T. H. Rabbitts, Z. R. Tehrani, M. M. Sajadi, R. W. Sanders, A. K. Sato, L. Schweizer, J. Seo, B. Shen, J. J. Snitselaar, **L. Stamatatos**, Y. Tan, M. T. Tomic, M. J. van Gils, S. Youssef, J. Yu, T. Z. Yuan, Q. Zhang, B. Peters, G. D. Tomaras, T. Germann, and E. Ollmann Saphire. 2021. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A Global Consortium study. *Science*. **374**; 472–478. [10.1126/science.abh2315](https://doi.org/10.1126/science.abh2315).
119. Zhao, L. P., T. P. Lybrand, P. B. Gilbert, T. R. Hawn, J. T. Schiffer, **L. Stamatatos**, T. H. Payne, L. N. Carpp, D. E. Geraghty and K. R. Jerome. 2021. Tracking SARS-CoV-2 Spike Protein Mutations in the United States. *Viruses*. **14**(1); 9 [doi.org/10.3390/v14010009](https://doi.org/10.3390/v14010009).
120. Beaudoin-Bussi eres, G., Y. Chen, I. Ullah, J. Pr evost, W. D. Tolbert, K. Symmes, S. Ding, M. Benlarbi, S. Y. Gong, A. Tauzin, R. Gasser, D. Chatterjee, D. V ezina, G. Goyette, J. Richard, F. Zhou, **L. Stamatatos**, A. T. McGuire, H. Charest, M. Roger, E. Pazharski, P. Kumar, W. Mothes, P. D. Uchil, M. Pazgier and A. Finzi. 2021. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a NAb to protect mice from lethal SARS-CoV-2 infection. *Cell Reports*. **38**; PMID: 35123652. PMCID: [PMC8786652](https://pubmed.ncbi.nlm.nih.gov/PMC8786652/) DOI: [10.1016/j.celrep.2022.110368](https://doi.org/10.1016/j.celrep.2022.110368)
121. Hurlburt, N. K.,<sup>@</sup> L. J. Homad<sup>@</sup>, I. Sinha, M. F. Jennewein, A. J. MacCamy, Y-H. Wan, J. Boonyaratanakornkit, A. M. Sholukh, P. Zhou, D. R. Burton, R. Andrabi, **L. Stamatatos**<sup>#</sup>, M. Pancera<sup>#</sup>, A. T. McGuire<sup>#</sup>. 2021. Structural definition of a pan-sarbecovirus 1 neutralizing epitope on the spike S2 subunit. *Communications Biology*. **5**; [342](https://doi.org/10.1038/s42003-022-03262-7) [doi.org/10.1038/s42003-022-03262-7](https://doi.org/10.1038/s42003-022-03262-7).
122. Gray, M.D., J. Feng, C. E. Weidle, K. W. Cohen, L. Ballweber-Fleming, A. J. MacCamy, C. N. Huynh, J. J. Trichka, D. Montefiori, G. Ferrari, M. Pancera<sup>#</sup>, M. J. McElrath<sup>#</sup> and **L. Stamatatos**<sup>#</sup>. 2022. A vaccine-elicited human antibody with sequence homology to VRC01-class antibodies binds the C1C2 gp120 domain: implications for HIV-1 vaccine-design. *Science Advances*. **8**; [eabm3948](https://doi.org/10.1126/science.adb3948).
123. Maria L. Knudsen<sup>@</sup>, P. Agrawal<sup>@</sup>, A. MacCamy, K. R. Parks, M. D. Gray, B. N. Takushi, A. Khechaduri, K.R. Salladay, R. N. Coler, C. C. LaBranche, D. Montefiori and **L. Stamatatos**<sup>&</sup>. 2022. Adjuvants influence the maturation of VRC01-like antibodies during immunization. *iScience*. **25**; [105473](https://doi.org/10.1016/j.isci.2022.105473), [doi.org/10.1016/j.isci.2022.105473](https://doi.org/10.1016/j.isci.2022.105473).
124. Noto, A., M. Suffiotti, V. Joo, A. Mancarella, F. A. Procopio, G. Cavet, Y. Leung, J.-M. Corpataux, M. Cavassini, A. Riva, **L. Stamatatos**, R. Gottardo, A. B. McDermott, R. A. Koup, C. Fenwick, M. Perreau and G. Pantaleo. 2022. The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection. *Front Immunol*. Aug 24; **13**:960120. [doi: 10.3389/fimmu.2022.960120](https://doi.org/10.3389/fimmu.2022.960120).
125. H aggl of, T., M. Cipolla; S. T. Chen; L. Mesin; H. Hartweger; M. A. El Tanbouly; A. Cho; A. Gazumyan; V. Ramos; **L. Stamatatos**; T. Y. Oliveira; M. C. Nussenzweig and C. Viant. 2023. Continuous Germinal Center Invasion Contributes to the Diversity of the Immune Response. *Cell*. **186**; 1-15, [doi.org/10.1016/j.cell.2022.11.032](https://doi.org/10.1016/j.cell.2022.11.032).
126. Gristick, H. B., H. Hartweger, M. Loewe, J. van Schooten, V. Ramos, T. Y. Oliviera, Y. Nishimura, N. S. Koranda, A. Wall, K-H. Yao, D. Poston, A. Gazumyan, M. Wiatr, M. Horning, J. R. Keefe, M. A.G. Hoffmann, Z. Yang, M. E. Abernathy, K-M. A. Dam, H. Gao, P. N.P. Gnanapragasam, L. M. Kakutani, A. J. Pavlovitch-Bedzyk, M. S. Seaman, M. Howarth, A. T. McGuire, **L. Stamatatos**, M. A. Martin, A. P. West, Jr, M. C. Nussenzweig and P. J. Bjorkman. 2023. CD4-binding site immunogens elicit heterologous anti-HIV-1

- neutralizing antibodies in transgenic and wildtype animals. *Science Immunology*. **8(80)**; eade6364.
127. Bale, S., L. Yang, M. Alirezael, R. Wilson, T. Ota, E.D. Doyle, C. Cottrell, J. Guenaga, K. Tran, W. Li, **L. Stamatatos**, D. Nemazee, A. B. Ward and R. T. Wyatt. 2023. Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response. *Frontiers*. doi.org/10.3389/fimmu.2023.1180959.
  128. Hahn, W.O., K. R. Parks, M. Shen, G. Ozorowski, H. Janes, L. Ballweber-Fleming, A. S. Woodward Davis, C. Duplessis, M. Tomai, A. K. Dey, Z. K. Sagawa, S. C. De Rosa, A. Seese, L. Kallur Siddaramaiah, **L. Stamatatos**, Wen-Hsin Lee, L. M. Sewall, D. Karlinsey, H. L. Turner, V. Rubin, S. Furth, K. MacPhee, M. Duff, L. Corey, M. C. Keefer, S. Edupuganti, I. Frank, J. Maenza, L. R. Baden, O. Hyrien, R. W. Sanders, J. P. Moore, A. B. Ward, G. D. Tomaras, D. C. Montefiori, N. Roupheal and M. J. McElrath. 2024. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. *The Journal of Experimental Medicine*. **221**; e20240604.
  129. Agrawal, P., M. L. Knudsen, A. MacCamy, N. K. Hurlburt, A. Khechaduri, K. R. Salladay, G. M. Kher, L. Kallur Siddaramaiah, A. B. Stuart, I. Bontjer, X. Shen, D. Montefiori, H. B. Gristick, P. J. Bjorkman, R. W. Sanders, M. Pancera and **L. Stamatatos**. 2024. Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env. *Accepted. Journal of Virology*.
  130. Termote, M., R. C. Marques, E. Hyllner, M. V. Guryleva, M. Henskens, A. Brutscher, I.J.L. Baken, X. Castro Dopico, A. Dalmau Gasull, B. Murrell **L. Stamatatos**, L. S. Westerberg, and P. Dosenovic. 2024. Antigen affinity and site of immunization dictate B cell recall responses. *Submitted*.

\* **Indicates: Most significant publications**

@ **Indicates: Equal contribution**

# **Indicates: Co-correspondence**

& **Indicates: Lead author**

## B. Book Chapters

1. Düzgünes, N., M.C. Pedroso de Lima, C.E. Larsen, **L. Stamatatos**, D. Flasher, D. Alford, D.S. Friend, and S. Nir. 1991. Fusion of influenza, sendai and simian immunodeficiency viruses with cell membranes and liposomes. In: *Cell and Model Membrane Interactions* (S. Ohki, ed.) Plenum Press, New York. Pg. 179-197.
2. Düzgünes, N., C.L. Larsen, **L. Stamatatos**, and K. Konopka. 1992. Fusion of immunodeficiency viruses with liposomes and cells: inhibition of human immunodeficiency virus type 1 infectivity by cardiolipin liposomes. In: *Membrane Interactions of HIV* (R. C. Aloia, C. C. Curtain and L. M. Gordon, eds.), Wiley-Liss, New York. Pg 317-327.
3. Barker, E., S.W. Barnett, **L. Stamatatos**, and J.A. Levy. 1995. The human immunodeficiency viruses. In: *The Retroviridae*, Vol. IV (J. A. Levy ed.), Plenum Press, New York. pg 1-96.

## C. Perspectives, Letters, Reviews and Reports

1. Donnelly, J.J., S.W. Barnett, A. Dorenbaum, and **L. Stamatatos**. 2002. Envelope-based HIV vaccines. *Science*. **297**; 1277-1278.
2. **Stamatatos, L.**, L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? *Nature Medicine*. **15**; 866-870.
3. Mascola, J., King, C. R. and Steinman, R on behalf of the **Working Group\*** convened by the Global HIV Vaccine Enterprise. 2010. Immunogens and antigen processing: report from a global HIV vaccine enterprise working group. *Nature Medicine*, October 2010 pg 12-16

(Originally published in Nature Proceedings 7 September 2010; doi:10.1038/npre.2010.4796.2).

**\* L. Stamatatos is a member of the Working Group**

3. McGuire, A. T. and **L. Stamatatos**. 2015. Common characteristics of HIV neutralizing antibodies with fondness for sugars. *Immunity*. **43**: 837- 840. (doi:10.1016/j.immuni.2015.10.026)

**D. Invited Refereed Publications**

1. Cheng-Mayer, C., **L. Stamatatos**, and A. Werner. 1992. Structure/Function relationships of the HIV-1 envelope gp120 in determining host cell tropism, cytopathicity, and sensitivity to sCD4 neutralization. *7<sup>e</sup> Colloque des Cent Gardes*, edited by Mark Girard, Louis Valette, PMSV, Paris, 5-10.
2. **Stamatatos, L.** and D. Davis. 2001. New insights into protective humoral responses and HIV vaccines. In: AIDS 2001: A year in Review. *AIDS* **15**; S105-S115.
3. Barnett, S.W., G. Otten, I. Srivastava, J. Zur Megede, Y. Lian, M.Schaefer, H. Liu, R. Deck, J. Donnelly, J. Polo, D O'Hagan, J. Ulmer, **L. Stamatatos**, D Montefiori, M. Lewis, S Engelbrecht, E Janse van Rensburg, G.Widera, X. Enhanced DNA prime-protein boost vaccines induce potent and protective immune responses against HIV-1. *XIIIth Cent Gardes Symposium*, Annecy, France, October 27-29, 2002. In *Retroviruses of Human AIDS and Related Animal Diseases*. M. Vicari, B. Dodet, M. Girards, Eds. Elsevier
4. Haigwood, L. N. and **L. Stamatatos**. 2004. Role of neutralizing antibodies in HIV infection. *AIDS Year in review*. *AIDS*, **7**(suppl. 4); S67-S71.
5. Hu, S.-L. and **L. Stamatatos**. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. *Current HIV Research*, **5**; 507-513,7p. PMID: 18045108
6. Schief, W.R., A. B. Yih-En Andrew, and **L. Stamatatos**. 2009. Challenges for Structure-based HIV Vaccine Design. *Current Opinion in HIV and AIDS*. **4**; 431-440. PMID: 20048708
7. **L. Stamatatos**. 2012. HIV Vaccine design: The neutralizing antibody conundrum. *Current Opinion in Immunology*, **24**; 316-323.
8. **L. Stamatatos**, M. Pancera and A. T. McGuire. 2017. Germline targeting immunogens. *Immunological Reviews*. **275**; 203-216. PMID: [PMC5741082](https://pubmed.ncbi.nlm.nih.gov/27541082/)
9. **L. Stamatatos**. 2023. Immunization during ART and ATI for HIV-1 vaccine discovery/development. *Current Opinion in HIV and AIDS*. **18**(6):309-314, PMID: [PMC10552831](https://pubmed.ncbi.nlm.nih.gov/410552831/)

**16. Other**

**A. Invited National and International Lectures**

1. Conference on HIV Pathogenesis, Keystone Symposia on Molecular and Cellular Biology, Keystone, Colorado, April 17-23 1995. Title of presentation: 'Exposure of the third hypervariable region on intact HIV-1 virions displaying macrophage- and T-cell line-tropism'.
2. Second Diamond Center AIDS Symposium, The Rockefeller University, New York, May 20, 1998. Title of presentation: 'Deletion of the V2 loop alters the neutralization-susceptibility of HIV'.
3. 1999 Winter Biotechnology Conference at Cold Spring Harbor, Molecular Approaches to Vaccine Design, Cold Spring Harbor, New York, December 2-5, 1999. Meeting on 'Molecular Approaches to Vaccine Design'. Title of presentation: 'Generation of T-helper and neutralizing antibody responses in macaques immunized with the SF162ΔV2 envelope using a bimodal DNA/protein vaccination protocol'.
4. WHO-UNAIDS Vaccine Advisory Committee Meeting, 'Approaches to the development of broadly protective HIV/AIDS vaccines: HIV subtypes and cross-reactive anti-HIV immune

- responses', Geneva, Switzerland, February 21-23, 2000. Title of presentation: 'Immunogenicity of SF162-derived envelope proteins'.
5. Conference on Vaccine Development and Immunotherapy in HIV, Palm Beach, Florida, June 28-July 1, 2000. Title of presentation: 'A modified HIV-1 envelope immunogen elicits neutralizing antibodies against heterologous primary HIV-1 isolates'.
  6. Seattle Biomedical Research Institute, Seattle, Washington, March 6, 2000. Title of presentation: 'Structural analysis and immunogenicity of SF162-derived envelope proteins'.
  7. University of Massachusetts, September 29, 2000. Title of presentation: 'Can modified HIV envelope immunogens elicit potent cross-reactive neutralizing antibodies?'.
  8. 18<sup>th</sup> Annual Symposium on Nonhuman Primate Models for AIDS, Madison, Wisconsin, October 4-7, 2000. Title of presentation: 'Vaccine-induced anti-HIV envelope antibodies protect CD8<sup>+</sup> T cell-depleted rhesus macaques from SHIV-challenge'.
  9. Fred Hutchinson Cancer Research Center, Seattle, Washington, November 9, 2000. Title of presentation: 'Designing of novel HIV envelope-based vaccines'.
  10. Third International Summit Meeting on Immunological Correlates of Protection, Sestri, Italy, November 30-December 3, 2000. Title of presentation: 'DNA-immunization with a modified HIV envelope elicits protective antibodies in macaques'.
  11. Tenth Diamond Center AIDS Symposium, The Rockefeller University, New York, April 17, 2001. Title of presentation: 'Induction of HIV neutralizing antibodies'.
  12. New York Blood Center, New York, June 12, 2001. Title of presentation: 'HIV envelope modifications that increase the exposure of neutralization epitopes'.
  13. 19<sup>th</sup> Annual Symposium on Non-Human Primate Models for AIDS, San Juan, Puerto Rico, November 7-10, 2001. Title of presentation: 'Generation of cross-reactive neutralizing and protective antibodies in macaques immunized with a modified HIV-1 envelope'.
  14. U.S.-Japan Cooperative Medical Science Program, 14<sup>th</sup> Joint Scientific Meeting of the AIDS panels, Seattle, WA, March 19-21, 2002. Title of presentation: 'Analysis of anti-HIV envelope responses in macaques immunized with SF162gp140 and  $\Delta$ V2gp140 immunogens and exposed to SHIV<sub>SF162P4</sub>'.
  15. Third AIDS Seminar in Kumamoto, Japan, September 20, 2002. Title of presentation: 'Modified HIV envelope immunogens: Can they elicit cross-reactive neutralizing antibodies?'.
  16. University of Washington, Department of Pathobiology, Seattle, WA, November 21, 2002. Title of presentation: "Modification of the HIV envelope: Effects on viral phenotype and implications for vaccine development".
  17. Keystone Symposia on HIV Vaccines, Banff, Alberta, Canada, March 29-April 4, 2003. Title of presentation: "Priming by vaccination of HIV envelope-specific B-cell responses allows for the long-term control of SHIV<sub>SF162P4</sub>-replication in macaques".
  18. FHCRC Symposium on Research at the Seattle Biomedical Research Institute, 2003. Title of presentation: "Engineering vaccines to overcome HIV antigenic variation".
  19. 21<sup>st</sup> Annual Symposium on Non-Human Primate Models for AIDS, Seattle, WA, October 23-26, 2003. Title of presentation: "Successful containment of viral replication in macaques infected with an R5-tropic SHIV depends on the early development of anti-envelope antibodies".
  20. Washington National Primate Research Center, Seattle, WA, May 26, 2004. Title of presentation: "Evolution in macaques of an R5-tropic SHIV in the absence and presence of a competing X4-tropic SHIV".
  21. Chiron Corporation, Emeryville, CA, July 20, 2004. Title of presentation: "HIV envelope modifications and the generation of protective antibodies".
  22. AIDS Vaccine 2004. Lausanne, Switzerland, August 30- September 1, 2004. Title of presentation: "HIV envelope modifications and the generation of protective antibodies".
  23. AIDS Vaccine 2005. Montreal, Canada, September 6-9, 2005. Title of presentation: "Viral escape in the presence of broadly reactive anti-HIV serum neutralizing antibodies".

24. 6<sup>th</sup> AIDS Seminar in Kumamoto International Symposium, Kumamoto, Japan, September 15-16, 2005. Title of presentation: "Continuous viral replication in the presence of broadly reactive anti-HIV serum neutralizing antibodies in macaques infected with an R5-SHIV".
25. SBRI Seminar Series, Seattle, WA, January 30, 2006. Title of presentation: "HIV, Neutralizing Antibodies, and Monkeys".
26. Keystone Symposia on HIV Vaccines, Keystone, Colorado, March 27-April 2, 2006. Title of presentation: "Distinct immunogenic properties of the SF162 Env on infectious virions and soluble gp140 proteins".
27. Aaron Diamond AIDS Research Center, New York, NY, April 23, 2007. Title of presentation: "Designing HIV Env immunogens: loops, twists, turns and dead ends".
28. Washington Technology Alliance, Discovery Series, Seattle, WA, June 8, 2007. Title of presentation: "Novel approaches to develop an HIV vaccine".
29. Viral Pathogenesis retreat, Fred Hutchinson Cancer Research Center, Seattle, WA, June 28, 2007. Title of presentation: "Novel approaches to HIV Env immunogen design".
30. Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Institute Symposium, Seattle, WA, July 16, 2007. Title of presentation: "New approaches to elicit cross reactive NAbs against HIV".
31. Uniformed Services University, Dept. of Defense, Bethesda, October 29, 2007. Title of presentation: "Comparing the neutralizing antibodies generated during HIV/SHIV-infection to those elicited by HIV Env immunogens".
32. HIV Vaccine Trials Network, Seattle, WA, November 8, 2007. Title of presentation: "Making HIV trimers".
33. B&MGF, Seattle, WA, February 4, 2008. Title of presentation: "Roadblocks in designing a vaccine against HIV that would elicit protective antibodies".
34. The 8<sup>th</sup> Awaji International forum on Infection and Immunity / US-Japan Cooperative Medical Science Program -21<sup>st</sup> Joint Meeting of the AIDS Panel, Awaji Island/Tokyo, September 7-12, 2008. Title of presentation: "Epitope specificities of cross-reactive NAbs in HIV+ plasma".
35. PATH, Seattle, WA, November 17-18, 2008: aids2031 – Discovery and Innovation for HIV/AIDS. Title of Presentation: "HIV vaccines".
36. The Collaboration for AIDS Vaccine Discovery, B&MGF, Seattle, WA, December 3-5, 2008: Multiple epitope-specificities in HIV+ sera containing cross-reactive NAbs. Can we elicit them by immunization?
37. Keystone Symposia on prevention of HIV/AIDS, Keystone, Colorado, March 22-27, 2009. Title of presentation: "Broad neutralizing antibody responses during HIV-1 infection: prevalence and epitope specificities".
38. NIH/ Vaccine Research Center, Bethesda, Maryland, April 21, 2009. Title of presentation: "Epitope specificities of cross-neutralizing antibody responses in HIV+ sera: implications for immunogen-design".
39. The American Association of Immunologists, 96<sup>th</sup> Annual meeting; Seattle, WA, May 8-12, 2009. Title of presentation: "Prevalence and epitope specificities of broadly-neutralizing antibodies generated during HIV-1 infection: how can we elicit them by vaccination?".
40. Marie Curie Conference on Immunology of HIV-1 and Tuberculosis infections; Nobel Forum; Karolinska Institute, Stockholm, Sweden; June 4-5 2009. Title of presentation: "HIV escape from naturally-occurring broadly-neutralizing antibodies: a pathway to disease progression?".
41. Symposium on "Co-Infection with HIV and the Hepatitis Viruses: an Asian Perspective"; Portland, Oregon, September 20-21, 2009; Title of presentation: "Cross-reactive anti-HIV Neutralizing Antibody Responses during 'Acute / Early' HIV-1 Infection".
42. AIDS Vaccine 2009. Paris, France, October 19-22, 2009. Title of presentation: "Eliciting broad anti-HIV neutralizing antibodies by vaccination: lessons learned from natural infection".

43. The 13th Annual CFAR Scientific Symposium, Vanderbilt, Tennessee, November 5, 2009. Title of presentation: "Cross-reactive neutralizing antibodies during acute and chronic HIV-1 infection".
44. Infectious Diseases Symposium /Virology Annual Conference, Seattle, Washington, January 5, 2010. Keynote Presentation: "Multiple HIV-1 escape pathways from B cell responses during acute and chronic HIV-1 infection".
45. Molecular Biology and Biochemistry Department at Simon Fraser University, Vancouver, BC, April 16, 2010. Title of presentation: "Characterization of the earliest cross-neutralizing antibody response to HIV-1".
46. 12<sup>th</sup> Annual International Meeting of IHV, Tropea, Italy October 4-8, 2010. Title of presentation: "Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1".
47. HIV Vaccine Trials Network, Washington DC, June 1-3, 2011. Panel Discussion on 'Selection of Envs Immunogens for upcoming efficacy trials'. Title of presentation: "Evaluation of clade A and other Envs for Env selection".
48. Global Health Research Congress on Vaccines, Seattle, WA, June 19-21, 2011. Panel Discussion on 'Harnessing advances in basic science to enable rational vaccine design'. Title of presentation: "Frequency and epitope-specificities of broadly neutralizing antibody responses during HIV-1 infection: implications for future vaccine-design strategies".
49. 13<sup>th</sup> Annual International Meeting of IHV, Baltimore, Maryland October 30-November 2, 2011. Title of presentation: "Interactions between HIV Env and germline versions of bNABs".
50. HIV Vaccine Trials Network, Seattle, WA, November 7-9, 2011. Title of presentation: "Envs from transmitted strains from vaccine trials".
51. The 2012 Palm Springs Symposium on HIV/AIDS "The Biology of HIV Infection", Palm Springs, CA, March 8-10, 2012. Title of presentation: "Broadly anti-HIV neutralizing antibodies, viral-escape and fitness costs".
52. AIDS Vaccine 2013. Barcelona, Spain, October 7-10, 2013. Title of presentation: "Recombinant Env interactions with B cell receptors of broadly neutralizing anti-HIV antibodies".
53. Institute for Systems Biology, Seattle Washington, November 18, 2013. Title of presentation: "Activating B cell receptors of broadly neutralizing anti-HIV antibodies and guiding their affinity maturation".
54. Seattle Biomedical Research Institute, March 10, 2014. Title of presentation: "Design and clinical testing of a conceptually novel HIV vaccine".
55. NIH/ Twinbrook Seminar, May 20, 2014. Title of presentation: "Activating the germline BCR form of a broadly neutralizing anti-HIV antibody by recombinant vaccines".
56. HIV Vaccine Trials Network, Washington, DC, June 3, 2014. Title of presentation: "Env immunogens designed to activate germline VRC01 class BCRs".
57. Fred Hutchinson Cancer Research Center, Seattle, WA, July 22, 2014. Title of presentation: "Activating the germline BCRs of anti-HIV-1 bnAbs by recombinant vaccines".
58. Cell & Gene Therapy for HIV cure, Seattle, WA, August 26, 2014. Title of presentation: "Immunogen-design efforts to activate the germline BCR forms of broadly neutralizing antibodies against HIV-1".
59. Les Cent Gardes, Veyrier de Lac, France, October 5-7, 2014. HIV Vaccines: Prospects for the future. Title of presentation: "Regulating the competition of progenitor BCRs of narrow and broadly neutralizing anti-HIV-1 antibodies by immunogen modification".
60. HIVR4, Cape Town, South Africa, October 28-31, 2014. Title of presentation: "HIV envelope interactions with the progenitor BCRs of narrow and broadly neutralizing antibodies".
61. Keystone Symposia, HIV Vaccines, Banff, Alberta, Canada, March 22-27, 2015. Title of presentation: "Characterization of Recombinant HIV-1 Envelopes that Bind Germline Forms of Broadly Neutralizing Antibodies".

62. SickKids, Molecular Structure & Function Seminar Series, Toronto, Ontario, Canada, September 21<sup>st</sup>, 2015. Title of presentation: “Germline BCRs of broadly neutralizing HIV-1 antibodies: How do they interact with HIV and how can we stimulate them during vaccination?”.
63. Protein Engineering Summit (PEGS), Boston, MA, April 25-29, 2016. Title of presentation: “Immunogen-design approaches to activate and mature the germline forms of broadly neutralizing HIV-1 antibodies”.
64. The Scripps Research Institute, Immunology and Microbial Sciences Seminar Series, San Diego, CA, May 12, 2016. Title of presentation: “Improving the odds of germline BCR-binding immunogens to succeed”.
65. University of Rochester, Microbiology and Immunology, Rochester, NY, September 19, 2016. Title of presentation: “Novel immunogens to initiate the development of HIV-1 broadly neutralizing antibodies during vaccination”.
66. B&MGF, The Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, December 6-8, 2016. Title of presentation: “Efforts to expand primary VRC01 antibody responses elicited by germline-targeting immunogens”.
67. The 2017 Neutralizing Antibody Consortium Meeting, San Diego, CA, March 6-7, 2017. Title of presentation: “Env-independent *in vivo* proliferation of B cells expressing precursor BCRs of bnAbs”.
68. AIDS Research Institute, Targeted Action Group Meeting, San Francisco, CA, April 18, 2017. Title of presentation: “The germline B cell receptor targeting’ approach for the elicitation of broadly neutralizing antibody responses to HIV-1”.
69. Karolinska Institute, Stockholm, Sweden, May 11, 2017. Title of presentation: “Approaches for the identification and *in vivo* expansion of rare B cells that express particular anti-viral B cell receptors”.
70. Les Cent Gardes, Veyrier de Lac, France, October 6-8, 2017. HIV Vaccines. Title of presentation: “Improving ‘on-target’ B cell-expansion during vaccination”.
71. B&MGF, The Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, December 5-7, 2017. Title of presentation: “Characterization of cross-reactive antibodies elicited by the 426c Core germline-targeting immunogen”.
72. Keystone Symposia on Cellular and Molecular Biology, Progress and Pathways towards an Effective HIV Vaccine, Banff, Alberta, Canada, January 28, 2018 – February 2, 2018. Title of presentation: “Targeted expansion and maturation of bNAb B cell precursors”.
73. NIH/NIAID Workshop on ““A Convergence Research Approach to an Effective HIV Vaccine””. Rockville, Maryland, September 24-25, 2018. Title of presentation: ‘Lineage-based vaccine design approaches’.
74. HIVR4P, Madrid, Spain, October 21-25, 2018. Title of presentation: ‘Germline-targeting immunization strategies to elicit diverse broadly neutralizing antibody responses’.
75. HIV Vaccine Trials Network (HVTN) Investigators meeting, Seattle, Washington, November 7, 2018. Title of presentation: ‘Phase 1 design: The 426c Core immunogen’.
76. B&MGF, The Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, December 4-6, 2018. Title of presentation: ‘Immunization strategies to overcome key steric barriers in the development of VRC01 bNAbs’.
77. Human Immunology Project Consortium (HIPC) Annual Meeting, NIH, Rockville, MD, March 27-28, 2019. Title of presentation: ‘High dimensional profiling of naive B cell heterogeneity to identify novel relationships with the generation of broadly neutralizing antibodies’.
78. Fred Hutchinson Cancer Research Center, Seattle, WA, June 4, 2019. Title of presentation: ‘Guiding the evolution of protective HIV-1 neutralizing antibodies by specifically-tailored immunogens’.



79. National Institute of Allergy and Infectious Diseases, NIH, October 23, 2020. Title of presentation: 'Dissecting the diverse mechanisms by which antibodies can neutralize SARS-CoV-2'.
80. International HIV Vaccine Initiative, Leadership Development Seminars, June 20, 2022. Title of presentation: 'Design of an HIV immunogen'.
81. HIV Vaccine Trials Network (HVTN) Conference, Seattle, October 17-20, 2022. Title of presentation: 'ATI role in boosting bnAb germ lines'.
82. Bill & Melinda Gates Foundation, 2023 CAVD Africa Regional Meeting, Cape Town South Africa, February 13-15, 2023. Title of presentation: 'The germline-targeting immunization approach: from discovery to clinical testing'.
83. HIV Vaccine Trials Network (HVTN) Full Group meeting, May 3-5, 2023. Title of presentation: 'HVTN301: 426c Modified Core VRC01 Priming'.
84. International HIV Vaccine Initiative, Leadership Development Seminars, September 28, 2023. Title of presentation: 'Design of an HIV immunogen'.
85. HIV Vaccine Trials Network (HVTN) meeting, October 16-18, 2023. Title of presentation: 'HVTN 301 – CD4bs VRC01-class antibody priming'.
86. HIV Vaccine Trials Network (HVTN) meeting, October 16-18, 2023. Title of presentation: 'Strategies for shepherding & policing broadly neutralizing antibody responses'.
87. The Scripps Consortium for HIV/AIDS Vaccine Development (CHAVID), 5<sup>th</sup> Annual Retreat, San Diego, January 31- February 2, 2024. Title of presentation: 'HVTN 301 phase 1 clinical trial'.
88. B&MGF, The Collaboration for AIDS Vaccine Discovery Meeting, Seattle, WA, February 6-8, 2024. Title of presentation: 'A four-Env prime-boost immunization scheme leads to the development of early VRC01-class cross-neutralizing antibodies in KI mice'.
89. The Scripps Research Institute, La Jolla, CA, April 4, 2024. Title of presentation: 'Clinical and Preclinical evaluation of immunogens that activate and guide the maturation of HIV-1 cross-neutralizing CD4-binding site antibody responses'.
90. NIH/DAIDS meeting "B cell Immune Repertoire Analysis for HIV Vaccines", August 13, 2024. Title of presentation: 'HVTN301: Germline-targeting 426c.Mod.Core nanoparticle + 3M-052/Alum'.

#### **B. Invited Presentations by Trainees**

21<sup>st</sup> Annual Symposium on Non-Human Primate Models for AIDS, Seattle, WA, October 23-26, 2003. Presenter: R. McCaffrey (postdoc). Title of presentation: "The effect of N-linked glycosylation of the V3 loop and the immunologically 'silent' face of gp120 on the HIV-1 SF162 viral phenotype".

US-Japan cooperative medical science program - 16th Joint scientific meeting of the AIDS panels, Nashville, TN, March 8-10, 2004. Presenter: R. McCaffrey (postdoc). Title of presentation: "The V3 loop and the immunologically 'silent' face of gp120 protect HIV-1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies".

Keystone Symposia on HIV vaccine development: progress and prospects, Whistler, Canada, April 12-18, 2004. Presenter: R. McCaffrey (postdoc). Title of presentation: "The immunologically 'silent' face of gp120 protects HIV-1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies".

AIDS Vaccine 2005. Montreal, Canada, September 6-9, 2005. Presenter: N. R. Derby (Graduate Student). Title of presentation: "Immunization with soluble oligomeric modified gp140s elicits neutralizing and enhancing antibodies".

AIDS Vaccine 2007. Seattle, Washington, August 21-23, 2007. Presenter: L. Ching (Graduate Student). Title of presentation: "Characterizing broadly reactive neutralizing antibody responses during HIV and SHIV infections".

Viral Pathogenesis Retreat 2008, Fred Hutchinson Cancer Research Center, June 2, 2008. Presenter: N. Sather (Postdoctoral fellow). Title of Presentation: "Factors associated with the emergence of cross-reactive NAbs is HIV-1 infection".

Keystone Symposia on HIV Vaccines, Keystone Co, March 2012. Presenter: S. Hoot (Postdoctoral fellow). Title of Presentation: "Interaction of germline precursor to broadly neutralizing anti-CD4 binding site antibody b12 with HIV-1 envelope glycoproteins".

Keystone Symposia: HIV Vaccines. Keystone, Colorado Feb 11, 2013. Presenter: A. McGuire (Postdoctoral fellow). Title of Presentation: Engaging the germline BCRs of anti-HIV bNAbs with modified recombinant Env immunogens.

ImmunoVancouver, Vancouver BC, Jun 13, 2013. Presenter: A. McGuire (Postdoctoral fellow). Title of Presentation: Glycans in the D loop and V5 of HIV Env restrict binding to, and activation of B cells expressing the germline BCRs of broadly neutralizing anti-HIV antibodies.

AIDS Vaccine, Barcelona Oct. 8, 2013. Presenter: A. McGuire (Postdoctoral fellow). Title of Presentation: Engineering an HIV Envelope Protein to Activate Germline B Cell Receptors of Broadly Neutralizing VRC01-Class Antibodies.

HIV Research for Prevention 2014, Cape Town, South Africa, October 28-31, 2014. Presenter: A. McGuire (Associate in Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center). Title of Presentation: Minimizing undesirable epitope immunodominance on HIV-1 Env immunogens through rational immunogen modification.

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center. Seattle, WA, January 13, 2015. A. McGuire (Associate in Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center). Title of Presentation: Antigen modification regulates competition between B cells that give rise to broad and narrow neutralizing HIV-1 antibodies.

UW/CFAR New Faces seminar series. Seattle, WA, January 18, 2015. Presenter: A. McGuire (Associate in Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center). Title of Presentation: Regulating the competition of progenitor BCRs of narrow and broadly neutralizing anti-HIV-1 antibodies by immunogen modification.

Awaji International Forum on Infection and Immunity, Awaji Island, Japan. September 11, 2015. A. McGuire (Associate in Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center). Title of Presentation: Immunogen design and optimization to target germline B cell receptors that give rise to broadly neutralizing antibodies against HIV-1.

Keystone Symposia: HIV Vaccines. Olympic Valley, California, March 20-24, 2016. Presenter: M. D. Gray. (Senior Scientist). Title of Presentation: Self-assembling HIV Envelope Nanoparticles Increase Antibody Binding, Membrane Dynamics and B-cell Activation

Keystone Symposia: HIV Vaccines. Olympic Valley, California, March 20-24, 2016. Presenter: C. Yacob (Postdoctoral fellow). Title of Presentation: Selective allelic expansion of HIV-1 immunized rhesus macaques based on different antigenic properties of Env immunogens.

HIVR4P 2016. Chicago, IL, October 17-21, 2016. Presenter: A. McGuire (Associate Scientist): Title of Presentation: 426c: A Clade C Env-Derived Germline VRC01 Targeting Immunogen.

HIVR4P 2016. Chicago, IL, October 17-21, 2016. Presenter: Pancera (Associate Scientist): Title of presentation: The Role of the CDRH3 of Germline VRC01-class Antibodies in HIV-1 Env Interactions.

HIVR4P 2016. Chicago, IL, October 17-21, 2016. Presenter: C. Yacob (Postdoctoral fellow): Title of presentation: Interactions of Putative Germline VRC01-Class Antibodies with HIV-1 Env: The Role of CDRH3.

Keystone Symposia: HIV Vaccines. Steamboat Springs, Colorado USA, March 26—30, 2017. Presenter: K. R. Parks (Graduate Student, University of Washington). Title of Presentation: Optimizing the Expansion of Primary VRC01 Antibody Responses by Germline-Targeting Immunogens.

## 17. Patents

US Patent US 2018, 0117140 and US 2019, 0321461 “ENGINEERED AND MULTIMERIZED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEINS AND USES THEREOF”. Issued 2019.

US Patent US 2021, 0308256 A1 “SEQUENTIAL IMMUNIZATION STRATEGIES TO GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS”